7DEOHRI&RQWHQWV
Table of Contents............................................................................................................. 1
Study 331-10-234 Protocol Amendment 03; 05 Jul 2022................................................ 2&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOLFGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Otsuka Pharmaceutical
Development & Commercialization, Inc.
Investigational Medicinal Product
Brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE])
REVISED CLINICAL PROTOCOL
A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to 
Evaluate the Efficacy of Brexpi[INVESTIGATOR_788412] 
(13-17 years old) With Schizophrenia
Protocol No. 331-10-[ADDRESS_1085587] No. 2017-001447-12
CONFIDENTIAL ‚Äì PROPRIETARY INFORMATION
Clinical Development Phase: 3
Sponsor: Otsuka Pharmaceutical Development & 
Commercialization, Inc.
[ADDRESS_1085588]
Rockville, Maryland [ZIP_CODE], [LOCATION_002]
Immediately Reportable Event Syneos Health Safety and 
Pharmacovigilance
Issue Date: 10 Mar 2017
Date of Amendment 1 24 Aug 2018
Administrat ive Change 1 31 May 2019
Date of Amendment 2 16 Jun 2020
Date of Amendment 3 05 Jul 2022
Version No.: 5.0Clinical Study Report 331-10-[ADDRESS_1085589] safety and maintain protocol requirements.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
3
Protocol 331-10-234
Confidential - Proprietary Information 3 Version 5.0, 05 Jul 2022 Protocol Synopsis 
Name [CONTACT_790]:  Otsuka Pharmaceutical 
Development & Commercialization, Inc.
Name [CONTACT_92732]:  
Brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE])Protocol No.:  331-10-234
IND No.:  101,[ADDRESS_1085590] No.:  2017-001447-12
Protocol Title: A Multicenter, Randomized, Double-blind, Placebo- and 
Active-controlled Trial to Evaluate the Efficacy of 
Brexpi[INVESTIGATOR_788412] 
(13-17 years old) With Schizophrenia
Clinical Phase/Trial 
Type:3/Therapeutic confirmatory
Treatment Indication: Schizophrenia
Objective(s): To evaluate the short-term efficacy and safety of brexpi[INVESTIGATOR_788413]: This is a multicenter, randomized, double-blind, placebo- and 
active-controlled trial designed to assess the effect of 
brexpi[INVESTIGATOR_788414], ages 
13 to 17 years, with a Diagnostic and Statistical Manual of 
Mental Disorders - Fifth Edition (DSM-5) diagnosis of 
schizophrenia.  The initial diagnosis of schizophrenia should 
be made by [CONTACT_276168] (psychiatrist or 
local medical equivalent who is experienced in treating 
adolescents with schizophrenia).  The diagnosis should then be 
confirmed by [CONTACT_788477]-Present and Lifetime version 
(K-SADS-PL), performed by [CONTACT_788478].  The trial is planned to be conducted on an 
outpatient basis.
This trial has a 6-week double-blind treatment period.
After a minimum 3-day washout period, subjects who continue 
to meet all entrance criteria (including Positive and Negative 
Syndrome Scale [PANSS] Total Score ‚â• 80) at the baseline 
visit (Day 1) will be randomized 1:1:1 to 1 of 3 double-blind 
treatment arms:
‚Ä¢brexpi[INVESTIGATOR_4253]
‚Ä¢aripi[INVESTIGATOR_4253] 
‚Ä¢PlaceboClinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
4
Protocol 331-10-234
Confidential - Proprietary Information 4 Version 5.0, 05 Jul 2022 Brexpi[INVESTIGATOR_788415] a minimum dose of 2 mg in 
8 days and aripi[INVESTIGATOR_788415] a minimum dose of 
10 mg, the therapeutic dose as per the [LOCATION_002] (US) 
package insert.  Subjects who are unable to tolerate the 
minimum dose will be discontinued.  At the end of the titration 
period, investigators will be able to adjust the dose of 
double-blind investigational medicinal product (IMP) not to 
exceed brexpi[INVESTIGATOR_4253] 4 mg/day or aripi[INVESTIGATOR_4253] [ADDRESS_1085591] dose 
increase, if the dose adjustment is not well tolerated, the dose 
may be reduced back to the minimum dose allowed by 
[CONTACT_990] (ie, brexpi[INVESTIGATOR_4253] 2 mg and aripi[INVESTIGATOR_4253] 10 mg).  
Subjects not able to tolerate the decreased dose will be 
discontinued from the trial.
Mandatory evaluations will take place at Day 1 (baseline), 
Day 4 (telephone call), and Weeks 1, 2, 3, 4, 5, and 6.  
However, at the discretion of the treating physician, more 
frequent evaluations are permitted.
Eligible subjects who complete the 6-week double-blind 
efficacy phase may have the option to enroll into an open-label 
safety trial of brexpi[INVESTIGATOR_4253] (Protocol 331-10-236).
All subjects who do not enroll in the open-label rollover trial 
(Protocol 331-10-236) will be assessed by a telephone 
assessment 21 (¬± 2) days after the last dose of IMP to assess 
adverse events (AEs).
Subject Population: The trial population will include male and female subjects 
between 13 and 17 years of age, inclusive, at the time of 
informed consent/assent and at baseline (Day 1) who continue 
to have a confirmed DSM-5 diagnosis of schizophrenia and a 
PANSS Total Score ‚â• 80 at screening and at baseline (Day 1).  
Approximately 645 subjects are anticipated to be screened 
with the expectation that 315 subjects will be randomized.
Inclusion/Exclusion 
Criteria: Subjects must meet the inclusion criteria at both screening and 
baseline.  Key inclusion criteria include the following:
‚Ä¢Subjects ages 13-17 inclusive at time of consent/assent and 
at baseline (Day 1) with a current primary diagnosis of 
schizophrenia, as defined by [CONTACT_2681]-[ADDRESS_1085592], and a history of the illness (diagnosis 
or symptoms) for at least 6 months prior to screening.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
5
Protocol 331-10-234
Confidential - Proprietary Information 5 Version 5.0, 05 Jul 2022 ‚Ä¢PANSS Total Score of ‚â• 80.
Key exclusion criteria include the following:
‚Ä¢Subjects with a DSM-5 diagnosis other than schizophrenia 
that has been the primary focus of treatment within 
3 months of screening.
‚Ä¢Subjects with a clinical presentation or history that is 
consistent with delirium, dementia, amnesia, or other 
cognitive disorders; subjects with psychotic symptoms that 
are better accounted for by [CONTACT_788479](s) or direct effect of a substance (eg, medication, 
illicit drug use).
‚Ä¢Subjects who have been hospi[INVESTIGATOR_057] > 21 days for a 
current exacerbation of schizophrenia at the time of the 
baseline visit.
‚Ä¢Subjects who are considered treatment resistant to 
antipsychotic medication, including aripi[INVESTIGATOR_788416], at an adequate dose and duration as 
confirmed by [CONTACT_9870], investigator judgment, or 
subject report.  Subjects with a history of relapse due to 
lack of medication compliance or drug abuse can be 
considered based on investigator judgment.
‚Ä¢Subjects who have a significant risk of committing violent 
acts, serious self-harm, or attempting suicide based on 
history (eg, suicide attempt in the past 1 year) or routine 
psychiatric status examination, or those who are homicidal 
or are considered to be a high risk to others, or who have 
an answer of ‚Äúyes‚Äù on Questions 4 or 5 (current or over the 
past 1 month) on the suicidal ideation section of the 
baseline screening version of the Columbia-Suicide 
Severity Rating Scale (C-SSRS).
‚Ä¢Subjects who have epi[INVESTIGATOR_002], a history of seizures (except 
for a single childhood febrile seizure or post-traumatic 
seizure), or a history of severe head trauma or stroke, or 
have a history or current evidence of other unstable 
medical conditions that would expose them to undue risk 
of a significant adverse event or interfere with assessments 
of safety or efficacy during the course of the trial, 
including but not limited to hepatic, renal, respi[INVESTIGATOR_696], 
cardiovascular, endocrine, neurologic, hematologic, or 
immunologic disease as determined by [CONTACT_511576] (eg, history of myocardial Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
6
Protocol 331-10-234
Confidential - Proprietary Information 6 Version 5.0, 05 Jul 2022 infarction or ischemic heart disease, arrhythmia, congestive 
heart failure, or cancer); subjects with a comorbid serious 
systemic illness that requires pharmacotherapy; subjects 
with any history of electroconvulsive therapy.
‚Ä¢Subjects who test positive for drugs of abuse at screening.  
A positive test for amphetamines, barbiturates, opi[INVESTIGATOR_858], 
benzodiazepi[INVESTIGATOR_788417] a 
result of prescription medicine(s).  When a subject tests 
positive for cannabinoids (tetrahydrocannabinol) at 
screening, the investigator is required to evaluate the 
subject's ability to abstain from using this substance during 
the trial and to discuss his/her evaluation with the Medical 
Advisor prior to randomization. 
Trial Sites: An estimated [ADDRESS_1085593] 
of the world (ROW) will enroll subjects.
Investigational 
Medicinal Product(s), 
Dose, Dosage 
regimen, Treatment 
period, Formulation, 
Mode of 
Administration:Brexpi[INVESTIGATOR_4253], aripi[INVESTIGATOR_4253], and placebo oral tablets will be 
supplied to the investigators by [CONTACT_788480]-resistant blister cards each containing sufficient 
tablets for the window visit.  When accessed by [CONTACT_779], an 
interactive web response system will assign a specific blister 
card to be dispensed to a subject.
For the 6-week double-blind treatment period, subjects will be 
randomized 1:1:1 to 1 of 3 double-blind treatment arms:
‚Ä¢2‚Äì4 mg brexpi[INVESTIGATOR_788418]
‚Ä¢10‚Äì20 mg aripi[INVESTIGATOR_788418] (subjects will start at 2 mg and 
titrate per label for adolescents diagnosed with 
schizophrenia)
‚Ä¢Placebo
For all subjects, the number of tablets taken during the titration 
period will be identical to ensure the double-blind nature of the 
trial.  Titration with brexpi[INVESTIGATOR_788419] 0.5 mg/day, 
increase to 1 mg/day, and increase again to 2 mg/day, which is 
the minimum dose.  Titration with aripi[INVESTIGATOR_788419] 
2 mg/day, increase to 5 mg/day, and increase again to 
10 mg/day, which is the minimum dose.  At the end of the 
titration period, investigators may either keep the subject at a 
maintenance dose or up-titrate by 1 mg (brexpi[INVESTIGATOR_4253]) or 
5 mg (aripi[INVESTIGATOR_4253]) to a maximum dose of 4 mg/day 
(brexpi[INVESTIGATOR_4253]) or 20 mg/day (aripi[INVESTIGATOR_4253]).Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
7
Protocol 331-10-234
Confidential - Proprietary Information 8 Version 5.0, 05 Jul 2022 ‚Ä¢Change in the Clinical Global Impression Severity (CGI-S) 
scale
‚Ä¢Clinical Global Impression Improvement (CGI-I) scale
Safety will be assessed by [CONTACT_716]:
‚Ä¢The frequency and severity of AEs, serious AEs (clinical 
and laboratory), and discontinuation from the trial due to 
AEs
‚Ä¢Weight, height, body mass index, and waist circumference
‚Ä¢Analysis of potential suicide events recorded on the 
C-SSRS
‚Ä¢Clinical laboratory tests and urinalysis results (including 
serum prolactin), vital signs, and ECG parameters
‚Ä¢Changes on the SAS, AIMS, and BARS
‚Ä¢Comprehensive psychotropic side effects as assessed by 
[CONTACT_788481]
‚Ä¢Cognitive adverse effects as assessed by [CONTACT_788482]-AACENT
Statistical Methods: Based on the results of the aripi[INVESTIGATOR_788420] (Protocol 31-03-239), 
aripi[INVESTIGATOR_4253] [ADDRESS_1085594] deviation (SD) at Week 6 was 19.  
Assuming that brexpi[INVESTIGATOR_4253] 2‚Äì[ADDRESS_1085595] 
80% power at a nominal 2-sided alpha level of 0.[ADDRESS_1085596] a 
‚àí7.4 point reduction in PANSS Total score change from 
baseline to Week 6 for brexpi[INVESTIGATOR_788421] = 19. With 1:1:[ADDRESS_1085597] is brexpi[INVESTIGATOR_4253] 2‚Äì4 mg vs. 
placebo.  With the assumption of missing at random (MAR), a 
mixed model repeated measures (MMRM) analysis with fixed 
effect factors of treatment, trial site, visit, treatment visit 
interaction, and fixed effect covariates baseline and baseline 
visit interaction will be applied to the change from baseline 
from Week 1 to Week 6 based on all available data (observed 
case dataset).  The data will be modeled using an unstructured 
variance covariance matrix for the within subject variation.  A Clinical Study Report 331-10-[ADDRESS_1085598] squares (LS) mean differences at 
Week 6 of the MMRM analysis will serve as the analysis of 
the primary endpoint.
In case there is a convergence problem with the MMRM 
model with the unstructured variance covariance matrix, the 
following structures other than unstructured will be used in 
order of 1) heterogeneous toeplitz, 2) heterogeneous 
autoregressive of order 1, and 3) heterogeneous compound 
symmetry, and the first (co)variance structure converging to 
the best fit will be used as the primary analysis.  If a structured 
covariance has to be used, the ‚Äúsandwich‚Äù estimator of the 
standard error of the fixed effects parameters will be used in 
order to deal with possible model misspecification of the 
covariance matrix.  
In order to explore the robustness of the primary analysis 
based on the MAR assumption, sensitivity analysis of the 
primary efficacy endpoint under a ‚Äúmissing not at random‚Äù 
assumption will be conducted, using a pattern-mixture model.
Trial Duration: Individual participation for subjects who complete the trial 
without early withdrawal will be approximately 13 weeks, 
consisting of a screening period of up to 28 days, a 6-week 
double-blind treatment period, and a 21 (¬± 2)-day follow-up, if 
applicable.  Subjects may have the option to enter an 
open-label rollover trial after completion of treatment.  Only 
subjects who do not participate in the open-label trial will be 
followed up via telephone contact 21 (¬± 2) days after the last 
dose of IMP.  Clinical Study Report 331-10-[ADDRESS_1085599] of Abbreviations and Definitions of Terms
Abbreviation Definition
ADHD Attention-deficit/hyperactivity disorder
ADT Antidepressant therapy
AE Adverse event
AIMS Abnormal Involuntary Movement Scale
ALP Alkaline phosphatase
ALT Alanine aminotransferase
ANCOVA Analysis of covariance
APO Apomorphine
AST Aspartate aminotransferase
AUC 0-24hArea under the concentration-time curve from time zero to [ADDRESS_1085600] 
observable concentration
BARS Barnes Akathisia Rating Scale
BUN Blood urea nitrogen
CGAS Children‚Äôs Global Assessment Scale
CGI-I Clinical Global Impression - Improvement scale
CGI-S Clinical Global Impression - Severity of Illness scale
CL/F Apparent clearance of drug from plasma after extravascular 
administration
Cmax,ssMaximum concentration at steady state
CMH Cochran-Mantel-Haenszel
CNS Central nervous system
CPK Creatine phosphokinase
CRO Clinical Research Organization
CIOMS Council for International Organizations of Medical Science
C-SSRS Columbia-Suicide Severity Rating Scale
CYP Cytochrome P450
D2 Dopamine D [ADDRESS_1085601] European Clinical Trial Data Base
FDA ([LOCATION_002]) Food and Drug Administration
GABA Gamma-aminobutyric acidClinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
19
Protocol 331-10-234
Confidential - Proprietary Information 19 Version 5.0, 05 Jul 2022 GAS Adult Global Assessment Scale
GCP Good Clinical Practice
GGT Gamma glutamyl transferase
GMR Geometric mean ratio
HbA1c Glycosylated hemoglobin
HDL High-density lipoprotein
5-HT1A Serotonin type 1A receptor
5-HT2A Serotonin type 2A receptor
IAF Informed assent form
IB Investigator‚Äôs brochure
ICF Informed consent form
ICH International Conference on Harmonisation
ICMJE International Committee of Medical Journal Editors
ID Identification
IDDM Insulin-dependent diabetes mellitus
IEC Independent ethics committee
IM Intramuscular
IMP Investigational medicinal product
IND Investigational New Drug
IRB Institutional review board
IRE Immediately reportable event
IR Immediate-release
ITT Intent-to-treat
IWRS Interactive web response system
K-SADS-PL Kiddie Schedule for Affective Disorders and Schizophrenia-Present 
and Lifetime version
KiInhibition constant
LDH Lactic dehydrogenase
LDL Low-density lipoprotein
LOCF Last observation carried forward
LS Least squares
MAOIs Monoamine oxidase inhibitors
MAR Missing at random
MedDRA Medical Dictionary for Regulatory Activities
MDD Major depressive disorder
MI Multiple imputation
MMRM Mixed model repeated measures
MNAR Missing not at random
MTD Maximum tolerated dose
NDA New Drug Application
NY-AACENT [LOCATION_001] Assessment for Adverse Cognitive Effects of 
Neuropsychiatric Treatment 
OC Observed case
OPC Otsuka Pharmaceutical Co.
PANSS Positive and Negative Syndrome ScaleClinical Study Report 331-10-[ADDRESS_1085602]-traumatic stress disorder
QD Once daily
QTc Corrected QT interval
QTcF QT interval as corrected for heart rate by [CONTACT_6550]‚Äôs formula
QTcN QT interval corrected for heart rate by [CONTACT_788483]
T4Thyroxine
TEAE Treatment-emergent adverse event
tmaxTime to maximum (peak) plasma concentration
TSH Thyroid-stimulating hormone
[LOCATION_006]U Udvalg for Kliniske Undersogelser
ULN Upper limit of normal
US or [LOCATION_003] [LOCATION_002] or [LOCATION_002] of America
WBC White blood cellClinical Study Report 331-10-[ADDRESS_1085603].  Brexpi[INVESTIGATOR_34788] (APO)-induced hyperlocomotion, 
APO-induced stereotyped behavior, and conditioned avoidance response in rats, which are predictive animal models for antipsychotic-like efficacy.  The inhibitory effects of 
brexpi[INVESTIGATOR_788422].  Moreover, in contrast to the 
D2 receptor antagonist risperidone, brexpi[INVESTIGATOR_788423]-treated rats, thus demonstrating a D 2 receptor partial agonistic profile in vivo.  
Despi[INVESTIGATOR_788424] D 2 receptor, the in vivo catalepsy liability of 
brexpi[INVESTIGATOR_4253], an index of EPS, was similar to that of aripi[INVESTIGATOR_4253], but still lower than 
that of the typi[INVESTIGATOR_788425].  Furthermore, brexpi[INVESTIGATOR_788426] 5-HT 2A receptor and dose-dependently inhibited 
(¬±)-2,5-dimethoxy-4-iodoamphetamine-induced head twitch response in rats, indicating 
that the compound has 5-HT 2A receptor antagonistic activity; the effect of brexpi[INVESTIGATOR_788427].  In addition, brexpi[INVESTIGATOR_788428] D [ADDRESS_1085604] at these 
receptors.
1.1.2 Safety Pharmacology
In safety pharmacology studies in rats at an oral dose of 30 mg/kg or higher, 
brexpi[INVESTIGATOR_788429] (CNS) and dose-dependent decreases in body 
temperature.  When orally administered at up to 30 mg/kg in conscious male beagle dogs, 
brexpi[INVESTIGATOR_788430].  
Brexpi[INVESTIGATOR_34798] 3 mg/kg or higher and prolonged both &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOLFGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331-10-234
Confidential - Proprietary Information 25 Version 5.0, 05 Jul 2022 Steady state PK also appeared to be linear following multiple daily doses of 
brexpi[INVESTIGATOR_34808] 0.5 to 2 mg to healthy subjects.  The accumulation factor 
based on maximum (peak) plasma concentration and area under the concentration-time 
curve calculated to the last observable concentration at time t was approximately 4 times.  
After multiple dose administration of brexpi[INVESTIGATOR_4253] (1 to 12 mg/day) to subjects with 
schizophrenia or schizoaffective disorder, brexpi[INVESTIGATOR_34807]-3411 mean terminal 
elimination half-life at steady state was 95.4 and 89.3 hours, respectively; median t max 
was 3.0 and 8.0 hours, respectively.
In drug interaction trials in healthy subjects, brexpi[INVESTIGATOR_788431] P450 (CYP) 3A4 and CYP2D6 isozymes and was not an inhibitor of 
CYP3A4, CYP2B6, CYP2D6, or P-glycoprotein.  Co-administration of potent CYP3A4 
or CYP2D6 inhibitors with brexpi[INVESTIGATOR_34810] a 2-fold higher exposure and 
about a 1.5-fold increase in the terminal elimination half-life of brexpi[INVESTIGATOR_4253].
In a single-dose trial in healthy subjects, approximately 46.0% and 24.6% of 
administered radioactivity following an oral dose of 14C-brexpi[INVESTIGATOR_34811], respectively.  In this same trial, brexpi[INVESTIGATOR_788432].  Brexpi[INVESTIGATOR_657414] 
(ÔÇ≥ 99.8%) in vitro.
The binding of brexpi[INVESTIGATOR_788433] (PET).  The mean D2/D3 receptor occupancies at [ADDRESS_1085605] dose after 0.25, 0.5, 1, 2, 4, 5, and 6 mg single-dose administration of brexpi[INVESTIGATOR_788434] 11.4% to 17.4%, 36.5% to 46.3%, 45.6% to 60.2%, 52.7% to 
68.6%, 67.9% to 79.5%, 71.9% to 88.2%, and 69.5% to 92.6%, respectively 
(Trial 331-07-202).  Based on the single-dose D2/D3 receptor occupancy data and 
steady-state PK/PD modeling, it was predicted that the D2/D3 receptor occupancy after 
multiple daily dose administration of [ADDRESS_1085606] 80% to 90% D2/D3 receptor occupancy.
1.2.2 Schizophrenia
The efficacy of brexpi[INVESTIGATOR_788435] 2 completed placebo-controlled trials 
(Trials 331-10-230 and 331-10-231), a long-term maintenance trial (Trial 331-10-232), 
and a long-term safety trial (Trial 331-10-237) and was approved for the treatment of 
schizophrenia in adults (ages 18 to 65) by [CONTACT_3557] 10 Jul 2015.  Trial 331-10-233 
was a phase 1, multicenter, open-label dose-escalation trial to assess the safety, Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
26
Protocol 331-10-234
Confidential - Proprietary Information 26 Version 5.0, 05 Jul 2022 tolerability, and PK of oral brexpi[INVESTIGATOR_788436].
In that trial, overall systemic exposure was measured by [CONTACT_2715]-normalized maximum 
concentration at steady state (C max,ss ) and area under the plasma concentration-time curve 
to the last observable concentration (AUC œÑ), and was slightly higher (geometric mean 
ratio [GMR] adult/adolescent:  0.765 and0.904, respectively), and apparent clearance of 
drug from plasma after extravascular administration (CL/F) was slightly lower (GMR 
adult/adolescent:  1.11) in adolescents compared to adults in the more important PK 
evaluable population.  For the less important PK population, slightly lower 
dose-normalized area under the concentration-time curve from time zero to 24 hours 
(AUC 0-24h) (GMR adult/adolescent:  1.05), and slightly higher dose-normalized C max 
(GMR adult/adolescent:  0.904) were observed in adolescents when compared to adults.  
The difference in the results for the two populations may be due to potential 
noncompliance, especially in the lower dose groups (0.5 and 1.0 mg), when dosing was 
not under medical supervision.
1.2.3 Major Depressive Disorder
The efficacy of brexpi[INVESTIGATOR_788437] 3 completed placebo-controlled trials (Trials 331-10-227, 331-10-228, and 
331-13-214) and a long-term, open-label safety trial (Trial 331-10-238).  The recently 
completed Trial 331-12-282 was a multicenter, randomized, double-blind, placebo and 
active comparator (Seroquel XR) controlled trial designed to assess the safety and 
efficacy of brexpi[INVESTIGATOR_4253] (flexible dose) as adjunctive therapy to an assigned open-label 
antidepressant therapy (ADT) in depressed subjects.  The trial was a continuous 18-week 
double-blind treatment period with a 30 (+ 2)-day follow up or entry into an optional 
open-label rollover trial.
1.2.4 Other Indications
Brexpi[INVESTIGATOR_788438] a proof-of-concept trial in adult ADHD 
(Trial 331-08-213).  This was a multicenter, randomized, double-blind, 
placebo-controlled, flexible dose trial in which adults with ADHD who had an 
incomplete/partial response to stimulant therapy in a prospective treatment phase were 
randomized to double-blind treatment with either brexpi[INVESTIGATOR_4253]-plus-stimulant or 
placebo-plus-stimulant.  This trial showed no statistically significant improvement with 
brexpi[INVESTIGATOR_788439].Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
27
Protocol 331-10-234
Confidential - Proprietary Information 28 Version 5.0, 05 Jul 2022 (IND) applications and 143 subjects (collectively) in non-US IND trials conducted in 
Japan and Korea.
Overall, 3101/4488 subjects (69.1%) who received brexpi[INVESTIGATOR_788440] 1 treatment-emergent 
adverse event (TEAE).  The most frequently reported TEAEs (incidence ‚â• 5% of the total 
brexpi[INVESTIGATOR_572542]) in all subjects who received 
brexpi[INVESTIGATOR_788441] (10.8%), increased weight (9.0%), insomnia (8.1%), 
akathisia (7.5%), dizziness (6.6%), somnolence (5.4%), and nausea (5.3%).  The majority 
of TEAEs reported in the [ADDRESS_1085607] been reported in the brexpi[INVESTIGATOR_788442]:  
25 deaths in the US IND trials and 1 death in the non-US IND trials.  Eight deaths 
occurred in schizophrenia trials, 10 deaths in MDD trials, and 8 deaths in the agitation 
associated with dementia of the Alzheimer‚Äôs type trials.  Three deaths occurred in 
completed trials, and the remaining [ADDRESS_1085608] been reported for 
94 subjects who received brexpi[INVESTIGATOR_34849] 45 completed trials, including 91 subjects 
in completed trials conducted under the US INDs and 3 subjects in completed non-US 
IND trials.  Serious TEAEs had been reported for 442 subjects in ongoing trials of 
brexpi[INVESTIGATOR_4253].
A total of 312/4488 subjects (7.0%) who received brexpi[INVESTIGATOR_4253] (either alone or 
coadministered with another medication) and 71/1378 subjects (5.2%) who received 
placebo (either alone or coadministered with another medication) discontinued from 
investigational medicinal product (IMP) due to TEAEs in completed brexpi[INVESTIGATOR_788443] (22 phase 1 trials, 1 phase 1b trial, 6 phase 2 trials, 
12 completed phase 3 trials, and 6 phase 3b trials).  A total of 2 subjects discontinued 
from IMP due to TEAEs in completed non-US IND trials, and 110 subjects discontinued 
from IMP due to TEAEs in the 2 ongoing non-US IND trials.  Brexpi[INVESTIGATOR_788444].  The recommended dose ranges are as follows:  
2 to 4 mg/day for the treatment of schizophrenia in adults and 2 to 3 mg/day in adult 
subjects with MDD.  The following dose ranges of brexpi[INVESTIGATOR_788445] 2/3, phase 3, and phase 3b clinical trials (by [CONTACT_35151]):  
0.5 to 2 mg/day in adult subjects with agitation associated with dementia of the 
Alzheimer‚Äôs type and 1 to 3 mg/day in adult subjects with PTSD.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
29
Protocol 331-10-234
Confidential - Proprietary Information 30 Version 5.0, 05 Jul 2022 Trial 331-10-233 were assigned to a dosing cohort and entered a Dose Titration Phase 
during which they received a starting dose of brexpi[INVESTIGATOR_4253] (0.5 mg or 1 mg) for 2 to 
10 days based on their assigned titration schedule.  Following the Dose Titration Phase, 
subjects entered the Fixed Dose Phase and were administered the assigned dose (0.5 mg 
to 4 mg) for that cohort for 14 days. For the final Cohort a Dose Titration of 1 mg on 
Days 1 and 2; 2 mg on Days 3 and 4; 2.5 mg on Days 5 and 6; 3 mg on Days 7 and 8; and 
3.5 mg on Days 9 and 10, followed by 4 mg daily for 14 days was followed.  
Brexpi[INVESTIGATOR_123150] 0.5 mg/day, 1 mg/day, 2 mg/day, 3 mg/day, and 4 mg/day was 
generally safe and well tolerated in adolescent subjects with schizophrenia, bipolar 
disorder, or other related psychiatric disorders.  Overall, systemic exposure and apparent 
clearance did not appear to be significantly different between adolescent and adult 
subjects while high variability due to limited number of evaluable subjects contributed to 
small differences between the PK evaluable and PK populations.
Based on results of pi[INVESTIGATOR_788446], a dose 
range of 2 to 4 mg is shown to be efficacious (Rexulti Label).  Based on the safety and 
PK data in Trial 331-10-233, no dose adjustment is deemed necessary in children and 
adolescents and thus a similar efficacious dose range of 2 to 4 mg is proposed for this 
trial.  In adult patients, brexpi[INVESTIGATOR_788447] 1 mg for 3 days followed by 2 mg for 
3 days, and a similar dose initiation is proposed in adolescent patients as a similar dose 
initiation scheme was evaluated in the final cohort of Trial 331-10-233 with no safety or 
tolerability concerns.  
2.3 Trial Objectives
The objective of the trial is to evaluate the short-term efficacy and safety of brexpi[INVESTIGATOR_788448].
3 Trial Design
3.1 Type/Design of Trial
This is a multicenter, randomized, double-blind, placebo- and active-controlled trial 
designed to assess the effect of brexpi[INVESTIGATOR_788414], 
ages 13 to 17 years at the time of informed consent/assent and at baseline (Day 1), with a 
Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) 
diagnosis of schizophrenia.  The initial diagnosis of schizophrenia should be made by [CONTACT_788484] (psychiatrist or local medical equivalent who is experienced 
in treating adolescents with schizophrenia).  The diagnosis should then be confirmed by 
[CONTACT_788485]-Present and Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
31
Protocol 331-10-234
Confidential - Proprietary Information 34 Version 5.0, 05 Jul 2022Table 3.2-1 Dosing Schedule During the Treatment Period
Trial 
Day/WeekBrexpi[INVESTIGATOR_4253] 
2‚Äì4 mg/dayAripi[INVESTIGATOR_4253] 
10‚Äì20 mg/dayPlacebo
Days 1-4 0.5 mg 2 mg placebo tablets QD
Days 5-7 1 mg 5 mg placebo tablets QD
Days 8-14 2 mg 10 mg placebo tablets QD
Days 15‚Äì21 2‚Äì3 mg with 
option to 
maintain 2 mg or 
increasea to 3 mg10 mg or 15 mg with 
option to maintain 10 mg 
or increasea to 15 mgplacebo tablets QD
Day 22+
(Weeks 4-6b)2, 3, or 4 mg with 
option to remain 
at the same dose, 
or increase or 
decrease dose by 
1 mg10, 15, or 20 mg with 
option to remain at the 
same dose, or increase or 
decrease dose by 5 mgplacebo tablets QD
QD = once daily.
aDose increases are allowed only at weekly intervals.  Dose decreases are allowed at any time for 
tolerability as long as the minimum required dose is maintained.
bBeginning at Day 22, the dose may be increased or decreased if needed for tolerability or efficacy.  
Subjects who cannot tolerate the minimum dose of [ADDRESS_1085609] to meals.
3.3 Trial Population
3.3.1 Number of Subjects and Description of Population
The trial population will include male and female subjects between 13 and 17 years of 
age, inclusive, at the time of informed consent/assent and at baseline (Day 1) who 
continue to have a confirmed DSM-5 diagnosis of schizophrenia and a PANSS Total 
Score ‚â• 80 at screening and at baseline (Day 1).  Approximately [ADDRESS_1085610] identification number upon 
signing the informed consent form (ICF) based on sequential enrollment in the trial.  
Subjects will be assigned a unique subject number upon enrollment, prior to dosing on 
Day 1.  The clinical site will maintain a list identifying all subjects by [CONTACT_788486].Clinical Study Report 331-10-[ADDRESS_1085611] be used:  vasectomy, tubal ligation, 
vaginal diaphragm, intrauterine device, birth control pi[INVESTIGATOR_4382], birth control implant, birth control 
patch, birth control depot injection, condom with spermicide, or sponge with spermicide.
2. Females who are breast-feeding or who have a positive pregnancy test result prior to receiving 
IMP.
Target Disease
3. Subjects with a DSM-5 diagnosis other than schizophrenia that has been the primary focus of 
treatment within 3 months of screening.
4. Subjects with a clinical presentation or history that is consistent with delirium, dementia, 
amnesia, or other cognitive disorders; subjects with psychotic symptoms that are better 
accounted for by [CONTACT_740887](s) or direct effect of a substance (eg, 
medication, illicit drug use).
5. Subjects who have been hospi[INVESTIGATOR_057] > 21 days for a current exacerbation of schizophrenia at the 
time of the baseline visit.
6. Subjects with known intellectual disability defined as an intelligence quotient less than 70; or, 
either clinical evidence or known social or school history indicative of intellectual disability.
7. Any neurological disorder, with the exception of Tourette‚Äôs Syndrome.
8. The subject is considered treatment resistant to antipsychotic medication, including aripi[INVESTIGATOR_788449], at an adequate dose and duration as confirmed by [CONTACT_9870], investigator 
judgment, or subject report.  Subjects with a history of relapse due to lack of medication 
compliance or drug abuse can be considered based on investigator judgment.
9. Subjects who have a significant risk of committing violent acts, serious self-harm, or suicide 
based on history (eg, suicide attempt in the past 1 year) or routine psychiatric status 
examination, or those who are homicidal or are considered to be a high risk to others, or who 
have an answer of ‚Äúyes‚Äù on Questions 4 or 5 (current or over the past 1 month) on the suicidal 
ideation section of the baseline screening version of the C-SSRS.
10. Subject is known to have medication compliance issues that lead to IM depot medication use.
Medical History and Concurrent Diseases
11. Subjects with current hypothyroidism or hyperthyroidism (unless the condition has been 
stabilized with medications for at least the past 90 days).  Eligibility of subjects that have an 
abnormal free T 4 result that is considered not clinically significant can be discussed with the 
Medical Advisor prior to randomization.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
38
Protocol 331-10-234
Confidential - Proprietary Information 38 Version 5.0, 05 Jul 2022Table 3.4.3-1 Exclusion Criteria
12. Subjects with IDDM are excluded.  Subjects with non-IDDM may be eligible for the trial if their 
condition is stable as determined by [CONTACT_35039]:
‚Ä¢HbA1c < 7.0%,
‚Ä¢Screening fasting glucose must be ‚â§ 125 mg/dL or non-fasting glucose < 200 mg/dL.  If the 
non-fasting glucose is ‚â• 200 mg/dL, subjects must be retested in the fasting state.  At retest, 
fasting glucose must be ‚â§ 125 mg/dL
‚Ä¢Subject has been maintained on a stable regimen of oral antidiabetic medication(s) for at 
least [ADDRESS_1085612] 
28 days prior to screening,
‚Ä¢Subject has not had any hospi[INVESTIGATOR_34867] 12 months prior to screening due to 
diabetes or complications related to diabetes, AND
‚Ä¢Subject‚Äôs diabetes is not newly diagnosed during screening for the trial.
13. Subjects with uncontrolled hypertension (DBP > 95 mmHg) or symptomatic hypotension, or 
orthostatic hypotension which is defined as a decrease of ‚â• 30 mmHg in SBP or a decrease of 
‚â• [ADDRESS_1085613] epi[INVESTIGATOR_002], a history of seizures (except for a single childhood febrile seizure or 
post-traumatic seizure), or a history of severe head trauma or stroke, or have a history or current 
evidence of other unstable medical conditions that would expose them to undue risk of a 
significant adverse event or interfere with assessments of safety or efficacy during the course of 
the trial, including but not limited to hepatic, renal, respi[INVESTIGATOR_696], cardiovascular, endocrine, 
neurologic, hematologic, or immunologic disease as determined by [CONTACT_788487] (eg, history of myocardial infarction or ischemic heart disease, arrhythmia, 
congestive heart failure, or cancer); subjects with a comorbid serious systemic illness that 
requires pharmacotherapy; subjects with a history of electroconvulsive therapy.
15. Subjects who test positive for drugs of abuse at screening are excluded.  A positive test for 
amphetamines, barbiturates, opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_788417] a result of prescription medicine(s).  When 
a subject tests positive for cannabinoids (tetrahydrocannabinol) at screening, the Investigator is 
required to evaluate the subject's ability to abstain from using this substance during the trial and 
to discuss his/her evaluation with the Medical Advisor prior to randomization.Clinical Study Report 331-10-[ADDRESS_1085614] and ECG results are exclusionary:
1) Platelets ‚â§ [ZIP_CODE]/mm3
2) Hemoglobin ‚â§ 11 g/dL
3) Neutrophils, absolute ‚â§ 1000/mm3
4) WBC count ‚â§ 2800/mm3
5) AST > 3 √ó upper limit of normal
6) ALT > 3 √ó upper limit of normal
7) Creatinine ÔÇ≥ 2 mg/dL
8) HbA1c ‚â• 7.0%
9) CPK > 3 √ó upper limit of normal
10) Abnormal free T 4, unless discussed with and approved by [CONTACT_612405].  (Note:  Free 
T4 is measured only if result for TSH is abnormal.)
11) QTcF or QTcN ÔÇ≥ 450 msec for males and ÔÇ≥ 470 msec for females
NOTE: In addition, subjects should be excluded if they have any other abnormal laboratory 
tests, vital sign results, or ECG findings which in the investigator‚Äôs judgment is medically 
significant and would impact the safety of the subject or the interpretation of the trial results.  
Criteria are provided to assist investigators in their assessments of results that may be potentially 
medically relevant, depending on the subject‚Äôs medical history and clinical presentation.  
Abnormal results for laboratory parameters or vital signs should be repeated [ADDRESS_1085615] 
meets the inclusion criteria.
Prohibited Therapi[INVESTIGATOR_678444]
17. Subjects who, according to the investigator‚Äôs judgment, will not be able to comply with the 
washout of psychotropic medications as defined by [CONTACT_760].
18. Subjects who would be likely to require prohibited concomitant therapy during the trial, 
including subjects receiving CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers at screening 
or who are anticipated to require use of such agents during the trial.
19. Subjects on IM depot therapy within 5 √ó half-life of the medication prior to screening.
Allergies and Adverse Drug Reactions
20. Subjects with a history of neuroleptic malignant syndrome.
21. Subjects with a history of true allergic response (ie, not intolerance) to more than one class of 
medications.
22. Subjects who report a true allergic response to aripi[INVESTIGATOR_788450].
Other
23. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) or involuntarily 
hospi[INVESTIGATOR_788451] a psychiatric or physical (eg, infectious disease) illness must 
not be enrolled into this trial.
24. Inability to tolerate oral medication or swallow tablets.
25. Subjects who participated in any clinical trial within the last [ADDRESS_1085616] who, in the opi[INVESTIGATOR_871], should not participate in the trial.
27. Subjects who are known poor metabolizers of CYP2D6 or CYP3A4.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
40
Protocol 331-10-234
Confidential - Proprietary Information 40 Version 5.0, 05 Jul 2022ALT = alanine aminotransferase; AST = aspartate aminotransferase; C-SSRS = Columbia-Suicide 
Severity Rating Scale; CPK = creatine phosphokinase; CYP = cytochrome P450; DBP = diastolic 
blood pressure; ECG = electrocardiogram; HbA1c = glycosylated hemoglobin; IDDM = insulin-
dependent diabetes mellitus; IM = intramuscular; QTcF = QT interval as corrected for heart rate by 
[CONTACT_6550]‚Äôs formula; QTcN = QT intervalcorrected for heart rate by [CONTACT_788488]; SBP = systolic blood pressure; T 4 = thyroxine; TSH = thyroid-stimulating hormone; 
WBC = white blood cell. 
Subjects must agree to restrictions to medications as described in Section 4.
Subjects excluded for positive drug/alcohol screen are not eligible to be rescreened for 
participation in the trial.  However, subjects excluded for any other reasons may be 
rescreened at any time if the exclusion characteristic has changed.  In the event that the 
subject is rescreened, a new ICF and assent must be signed and a new screening number 
assigned. 
3.5 Endpoints
3.5.1 Primary Endpoint
The primary endpoint is as follows:
‚Ä¢Change from baseline to Week 6 in PANSS Total Score
The estimand of the primary efficacy endpoint is described in Section 7.4.
3.5.2 Secondary Endpoints
[IP_ADDRESS] Secondary Efficacy Endpoints
The secondary efficacy endpoints are as follows:
‚Ä¢Change in the PANSS Positive and Negative Subscale Scores
‚Ä¢Percentage of subjects achieving response.  Response is defined as at least 30% 
improvement from baseline in PANSS Total Score or CGI score of 1 or 2.
‚Ä¢Percentage of subjects achieving remission.  Remission is defined as a score of ‚â§ 3 on 
each of the following specific PANSS items: delusions (P1), unusual thought content 
(G9), hallucinatory behavior (P3), conceptual disorganization (P2). 
mannerisms/posturing (G5), blunted affect (N1), passive/apathetic social withdrawal 
(N4), and lack of spontaneity and conversation flow (N6).
‚Ä¢Change in the Children‚Äôs Global Assessment Scale (CGAS) Score
‚Ä¢Change in the Clinical Global Impression Severity (CGI-S) scale
‚Ä¢Clinical Global Impression Improvement (CGI-I) scaleClinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
41
Protocol 331-10-234
Confidential - Proprietary Information 41 Version 5.0, 05 Jul [ZIP_CODE].5.2.2 Secondary Safety Endpoints
Safety will be assessed by [CONTACT_716]:
‚Ä¢The frequency and severity of AEs, serious AEs (clinical and laboratory), and 
discontinuation from the trial due to AEs
‚Ä¢Weight, height, body mass index, and waist circumference
‚Ä¢Analysis of potential suicide events recorded on the Columbia-Suicide Severity Rating Scale (C-SSRS)
‚Ä¢Clinical laboratory tests and urinalysis results (including serum prolactin), vital signs, physical examinations, and electrocardiogram (ECG) parameters
‚Ä¢Changes on the Simpson Angus Scale (SAS), Abnormal Involuntary Movement Scale (AIMS), and Barnes Akathisia Rating Scale (BARS)
‚Ä¢Comprehensive psychotropic side effects as assessed by [CONTACT_788489] ([LOCATION_006]U) side effect rating scale
‚Ä¢Cognitive adverse effects as assessed by [CONTACT_788490] (NY-AACENT)
3.6 Measures to Minimize/Avoid Bias
Subjects will be randomly assigned through an IWRS to receive brexpi[INVESTIGATOR_4253], 
aripi[INVESTIGATOR_4253], or placebo.  The randomized treatments will be administered in a double-blind fashion.  Treatment assignments will be based on a computer-generated randomization code provided by [CONTACT_572597] & Commercialization, Inc. Biometrics Department.
Sponsor personnel, including those involved in monitoring, data management, and data 
analysis, will not have access to the treatment code during the trial.  Access to the treatment codes will be restricted to personnel charged with generating and maintaining randomization files, packaging IMP, operating the IWRS, and reporting serious adverse events (SAEs) to regulatory agencies.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOLFGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331-10-234
Confidential - Proprietary Information 43 Version 5.0, 05 Jul 2022Table 3.7-1 Schedule of Assessments 
6-Week Double-blind Treatment PeriodFollow-up 
Visit
Assessment Screening
Day 1Day 4a
(¬± 1 
day)Week 1
(¬± 2 
days)Week 2
(¬± 2 
days)Week 3
(¬± 2 
days)Week 4
(¬± 2 
days)Week 
5
(¬± 2 
days)Week 6/ET
(¬± 2 days)21 (¬± 2) 
days after 
last dose 
of IMP
Informed consent, demography, 
medical history, psychiatric historyX
Entrance criteria X X
Prior medications X X
K-SADS-PL X
PANSS X X X X X X X X
CGAS X X X X X X X X
CGI-S X X X X X X X
CGI-I X X X X X X
P-Q-LES-Q X X
C-SSRS X X X X X X X
SAS, AIMS, BARS X X X X X X X X
[LOCATION_006]U X X X X X X X X
NY-AACENT X X X X X X X X
Tanner Stagingb X X
Physical examination X X
Body weight and waist 
circumferenceX X X X X X X X
Height X X
Dispense Investigational Product X X X X X X
Clinical laboratory tests 
(hematology, serum chemistry 
[including blinded prolactin], and 
urinalysis)X X X X
HbA1c and TSH X X XClinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
44
Protocol 331-10-234
Confidential - Proprietary Information 44 Version 5.0, 05 Jul 2022Table 3.7-1 Schedule of Assessments 
6-Week Double-blind Treatment PeriodFollow-up 
Visit
Assessment Screening
Day 1Day 4a
(¬± 1 
day)Week 1
(¬± 2 
days)Week 2
(¬± 2 
days)Week 3
(¬± 2 
days)Week 4
(¬± 2 
days)Week 
5
(¬± 2 
days)Week 6/ET
(¬± 2 days)21 (¬± 2) 
days after 
last dose 
of IMP
Vital signs (supi[INVESTIGATOR_050], sitting, and 
standing blood pressure, body 
temperature and pulse)cX X X X X X X X
ECG X XdXd
Serum pregnancy test X X X X
Urine pregnancy teste X X X
Urine drug screen XfXfXf
Pharmacokinetic samples XgXgXg
Pharmacogenomic sample X
Adverse events X X X X X X X X X X
Concomitant medications X X X X X X X X X X
ET = early termination.
aThe Day [ADDRESS_1085617], trial affiliated pediatrician, nurse-practitioner, or nurse (in case of countries or states where nurses are qualified to perform a complete physical 
examination).  When Tanner Staging is not completed at a required visit, it should be collected at the next trial visit. A subject who reaches Stage 5 (both in 
pubic hair and genitalia) does not need to continue with Tanner Staging. Any psychiatrist who will perform the Tanner Staging evaluation will be trained 
and required to demonstrate inter-rater reliability before receiving certification to conduct the evaluation. A family practitioner or pediatrician who are 
investigators are considered trained and do not need to go through formal inter-rater reliability. Sites should make attempts to have examiners of both 
gender types. Attempts should be made to have the examination performed by [CONTACT_788491]. Otherwise, a trial-affiliated personnel of the 
same gender (ie, nurse) as the subject should be in the same examination room as the subject.
cVital Signs ‚Äì refers to pulse and heart rate interchangeably throughout the protocol.
dAn ECG will be obtained predose on Day [ADDRESS_1085618], is required at the designated times, but either or both can be conducted at any time during the phase at the 
discretion of the investigator.
gA plasma PK sample will be obtained 1‚Äì[ADDRESS_1085619] 3 doses of IMP will also be recorded.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
46
Protocol 331-10-234
Confidential - Proprietary Information 48 Version 5.0, 05 Jul [ZIP_CODE].7.1.2 Baseline/Day 1 (Randomization)
If the subject is found to be eligible for the trial during the screening period, the subject 
will attend a baseline visit during which the following procedures will be completed prior 
to randomization:
‚Ä¢Inclusion/exclusion criteria will be verified.  Review of inclusion/exclusion criteria at 
the baseline visit will be based on assessments performed during screening.
‚Ä¢Prior medications will be reviewed.
‚Ä¢A qualified and certified rater will administer the PANSS.
‚Ä¢A qualified rater will administer the CGAS.
‚Ä¢A qualified and certified rater will administer the CGI-S.
‚Ä¢The P-Q-LES-Q assessment will be completed by [CONTACT_423].
‚Ä¢The investigator (or qualified designee) will complete the ‚ÄúBaseline/Screening‚Äù 
C-SSRS form.
‚Ä¢The investigator (or qualified designee) will administer the SAS, AIMS, and BARS.
‚Ä¢The investigator (or qualified designee) will administer the [LOCATION_006]U and NY-AACENT.
‚Ä¢Body weight and waist circumference will be recorded.
‚Ä¢Vital sign measurements (including blood pressure, body temperature, and pulse) 
will be recorded.  Blood pressure and pulse are to be measured in the following 
order:  supi[INVESTIGATOR_050], sitting, and standing after the subject has been in each position at 
least 3 minutes.  Vital signs are to be completed before any blood is drawn.
‚Ä¢A standard 12-lead ECG will be performed predose after the subject has been supi[INVESTIGATOR_788452] 5 minutes.  The ECG is to be completed before any blood is 
drawn. 
‚Ä¢Blood samples will be collected for clinical laboratory tests (hematology and serum 
chemistry [including blinded prolactin, HbA1c, and TSH]) after a minimum 8-hour 
fast, if fasting is possible.  Vital sign and ECG assessments should be completed 
before any blood samples are collected.
‚Ä¢A urine pregnancy test will be performed predose for all females.  The result must be 
negative prior to dosing.
‚Ä¢A serum pregnancy test will be collected for all females.
‚Ä¢Blood will be drawn for a plasma PK sample, which will be obtained 1‚Äì6 hours 
postdose, and the sampling time will be recorded.
‚Ä¢A pharmacogenomics (PGx) sample will be collected to determine the CYP2D6 
metabolizer status.
‚Ä¢AEs and concomitant medications will be recorded.
‚Ä¢If the subject remains eligible for the trial after completion of the baseline 
evaluations, trial personnel will capture trial data within the eSource and randomize 
the subject to obtain an IMP assignment.  The subject will receive the first dose of Clinical Study Report 331-10-[ADDRESS_1085620] 
dose will be recorded in eSource.
[IP_ADDRESS] Day [ADDRESS_1085621] AEs and concomitant 
medications.
[IP_ADDRESS] Weeks 1, 2, 3, 4, and 5
All subjects will be assessed weekly at scheduled visits during double-blind treatment in 
the acute treatment phase.  The following evaluations will be performed at each visit 
(ie, Weeks 1, 2, 3, 4, and 5):
‚Ä¢A qualified rater will administer the PANSS.
‚Ä¢A qualified rater will administer the CGAS.
‚Ä¢A qualified rater will administer the CGI-I.
‚Ä¢A qualified rater will administer the CGI-S.
‚Ä¢The investigator (or qualified designee) will complete the ‚ÄúSince Last Visit‚Äù C-SSRS 
form.
‚Ä¢The investigator (or qualified designee) will administer the SAS, AIMS, and BARS.
‚Ä¢The investigator (or qualified designee) will administer the [LOCATION_006]U and NY-AACENT.
‚Ä¢Body weight and waist circumference will be recorded.
‚Ä¢Vital sign measurements (including blood pressure, body temperature, and pulse) 
will be recorded.  Blood pressure and pulse are to be measured in the following 
order:  supi[INVESTIGATOR_050], sitting, and standing after the subject has been in each position at 
least 3 minutes.  Vital signs are to be completed before any blood is drawn, if 
applicable at the specific visit.
‚Ä¢Drug accountability.
‚Ä¢AEs and concomitant medications will be recorded.
‚Ä¢The IMP will be dispensed to the subject.
The following additional evaluations will be performed at Week 4 only :
‚Ä¢Blood samples will be collected for clinical laboratory tests (hematology and serum 
chemistry [including blinded prolactin]) after a minimum 8-hour fast, if fasting is 
possible.  Vital sign assessments should be completed before any blood samples are 
collected.
‚Ä¢Urine will be collected from all potential subjects for urinalysis and urine screen(s) 
for drugs of abuse.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
50
Protocol 331-10-234
Confidential - Proprietary Information 50 Version 5.0, 05 Jul 2022‚Ä¢A plasma PK sample will be obtained within 1-[ADDRESS_1085622] 3 doses of IMP will be 
recorded.
‚Ä¢A serum pregnancy test will be performed for all females.
[IP_ADDRESS] Week 6 (End of Treatment)
The treatment period will conclude at the Week [ADDRESS_1085623] typi[INVESTIGATOR_788453].  The following activities and assessments 
will occur at Week 6/end of treatment:
‚Ä¢Trial personnel will register completion or discontinuation from the trial in eSource.
‚Ä¢A qualified and certified rater will administer the PANSS.
‚Ä¢A qualified rater will administer the CGAS.
‚Ä¢A qualified and certified rater will administer the CGI-S.
‚Ä¢A qualified and certified rater will administer the CGI-I.
‚Ä¢The P-Q-LES-Q assessment will be completed by [CONTACT_423].
‚Ä¢The investigator (or qualified designee) will complete the ‚ÄúSince Last Visit‚Äù C-SSRS 
form.
‚Ä¢The investigator (or qualified designee) will administer the SAS, AIMS, and BARS.
‚Ä¢The investigator (or qualified designee) will administer the [LOCATION_006]U and NY-AACENT.
‚Ä¢The investigator (or qualified designee) will complete Tanner Staging assessment.
‚Ä¢A physical examination will be performed.
‚Ä¢Body weight, height, and waist circumference will be recorded.
‚Ä¢Vital sign measurements (including blood pressure, body temperature, and pulse) 
will be recorded.  Blood pressure and pulse are to be measured in the following 
order:  supi[INVESTIGATOR_050], sitting, and standing after the subject has been in each position at 
least 3 minutes.  Vital signs are to be completed before any blood is drawn.
‚Ä¢A standard 12-lead ECG will be performed postdose after the subject has been supi[INVESTIGATOR_788452] 5 minutes.  The ECG is to be completed before any blood is 
drawn.
‚Ä¢Blood samples will be collected for clinical laboratory tests (hematology and serum 
chemistry [including blinded prolactin, HbA1c, and TSH]) after a minimum 8-hour 
fast, if fasting is possible.  Vital sign and ECG assessments should be completed 
before any blood samples are collected.
‚Ä¢A urine pregnancy test will be performed predose for all females.
‚Ä¢A serum pregnancy test will be performed for all females.Clinical Study Report 331-10-[ADDRESS_1085624] Discontinuation
[IP_ADDRESS] Treatment Interruption
All attempts should be made to avoid treatment interruption during the trial.  For subjects 
who have an interruption of treatment, the investigator or designee will contact [CONTACT_788492].  The sponsor should be notified when 
there is a planned or inadvertent treatment interruption of [ADDRESS_1085625]‚Äôs continuation in the trial.  This decision will be documented by [CONTACT_788493].  The treatment interruption 
will be recorded via eSource and also recorded as a protocol deviation (Section 3.13).
[IP_ADDRESS] Treatment Discontinuation
After randomization, a subject may stop treatment permanently for a variety of reasons.  
Treatment discontinuations may be initiated by a subject who is not satisfied with 
treatment or may become medically necessary due to AEs, required treatment with a 
disallowed medication or therapy, or other issues, as determined by [CONTACT_093].  
However, each investigator must comprehensively review the circumstances and offer the 
subject options for continued treatment to the degree possible as described in 
Section [IP_ADDRESS].
If a subject discontinues from the trial prematurely, the reason must be fully evaluated 
and recorded appropriately in source documents and in eSource.  If the subject is being 
withdrawn because of an AE, that AE should be indicated as the reason for withdrawal.  
All subjects have the right to withdraw at any point during treatment without prejudice.  
The investigator can discontinue a subject‚Äôs participation in the trial at any time if 
medically necessary.  
[IP_ADDRESS] Documenting Reasons for Treatment Discontinuation
Subjects meeting any of the following criteria must discontinue IMP and be withdrawn 
from the trial:
a) occurrence of any AE, intercurrent illness or abnormality in a laboratory assessment 
which, in the opi[INVESTIGATOR_871], warrants the subject‚Äôs permanent withdrawal 
from the trial;
b) treatment with a prohibited concomitant medication other than the use of appropriate 
medications for the treatment of AEs under direction of the investigator;
c) subject noncompliance, defined as refusal or inability to adhere to the trial schedule 
or procedures (see Section 3.12);Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
63
Protocol 331-10-234
Confidential - Proprietary Information 63 Version 5.0, 05 Jul 2022d) at the request of the subject, investigator, sponsor or designee, or regulatory authority;
e) subject becomes pregnant (see Section 5.5);
f) subject cannot tolerate the assigned dose of IMP;
g) subject is lost to follow-up;
h) death;
i) subject withdraws informed consent; or
j) termination of all or part of the trial by [CONTACT_456].
The investigator will notify the sponsor promptly when a subject is withdrawn.  Subjects 
withdrawn prior to Week [ADDRESS_1085626] complete the Week 6 evaluations at the time of 
withdrawal.  In addition, all subjects who withdraw prematurely from the trial will be 
assessed by a telephone assessment 21 (¬± 2) days after the last dose of IMP for evaluation 
of safety.  Withdrawn subjects will not be replaced.
[IP_ADDRESS] Withdrawal of Consent
All subjects have the right to withdraw their consent from further participation in the trial 
at any time without prejudice.  Subjects‚Äô parents or legal guardians can also withdraw 
their consent to allow subjects to continue participation in the trial.  Subjects cannot 
withdraw consent for use of data already collected as part of the trial, but only for future 
participation.  The investigator can also discontinue a subject‚Äôs participation in the trial at 
any time if medically necessary.  Unless the subject provides their written withdrawal of 
consent or there is other written documentation by [CONTACT_788494]‚Äôs verbal intent to completely withdraw from the trial, subjects should be followed 
for all protocol-specified evaluations and assessments, if possible.
Complete withdrawal of consent requires a subject‚Äôs refusal of ALL of the following 
methods of follow up:
‚Ä¢Participation in all follow-up procedures specified in the protocol (whether in-clinic, 
by [CONTACT_756], or by [CONTACT_28920]-home visit).
‚Ä¢Participation in a subset of protocol specified follow-up procedures (by a frequency 
schedule and method, as agreed by [CONTACT_330210]).
‚Ä¢Contact [CONTACT_330211], even if only by [CONTACT_756], to assess current 
medical condition, and obtain necessary medical or laboratory reports relevant to the 
trial‚Äôs objectives.
‚Ä¢Contact [CONTACT_308705](s) who have been designated in source records as being 
available to discuss the subject‚Äôs medical condition, even if only by [CONTACT_756], mail, 
or e-mail (eg, family, spouse, partner, legal representative, friend, neighbor, or 
physician).Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
64
Protocol 331-10-234
Confidential - Proprietary Information 64 Version 5.0, 05 Jul 2022‚Ä¢Access to medical information from alternative sources (eg, hospi[INVESTIGATOR_307]/clinic medical 
records, referring doctor‚Äôs notes, public records, dialysis, transplantation or vital 
registries, social media sources). 
Withdrawal of consent is a critical trial event and therefore should be approached with 
the same degree of importance and care as is used in initially obtaining informed consent.  
The reasons for a subject‚Äôs intended withdrawal need to be completely understood, 
documented, and managed to protect the rights of the subject and the integrity of the trial.  
A subject may initially express their desire to interrupt or discontinue IMP 
administration, which is not equivalent to a complete withdrawal of consent for further 
participation (see Section [IP_ADDRESS] and Section [IP_ADDRESS]).  A subject ma y, however, indicate 
that further trial participation is creating a burden on their work or social schedule.  
Therefore, the investigator should follow the procedures outlined in Section [IP_ADDRESS] to 
determine if the subject can continue participation in the trial if modifications to his/her 
treatment or schedule of assessments can be accommodated.  Only subjects who 
withdraw their permission for all of the above degrees of follow up are considered to 
have completely withdrawn their consent to participate in the trial.
[IP_ADDRESS] Procedures to Encourage Continued Trial Participation
In all cases of impending IMP discontinuation or consent withdrawal, investigators will 
be given instructions to meet and discuss with the subject their options of continuing in 
the trial, preferably on therapy.  The investigator should ensure understanding and 
documentation of the reasons for the subject‚Äôs desire to withdraw consent.  
3.[ADDRESS_1085627] is one from whom informed consent is obtained and is 
documented in writing (ie, subject signs an ICF), but who is not started on treatment, 
whether through randomization or open assignment.  For the purposes of this trial, 
treatment begins with the first dose of double-blind IMP at the baseline visit.  If a subject 
fails to qualify for the trial during screening for a reason other than a positive screen for 
drugs of abuse, he/she is permitted to be rescreened at a later date.  In the event that a 
screen failure is rescreened for trial participation after the 28-day screening period 
expi[INVESTIGATOR_6054], a new ICF must be signed and a new screening number assigned.
3.[ADDRESS_1085628]-treatment follow-up contacts will not qualify as the ‚Äúlast scheduled visit.‚Äù  
Subjects who are not completers are defined as those who ‚Äúdiscontinued the trial.‚Äù
3.[ADDRESS_1085629] a known reason for discontinuation (eg, withdrew consent or 
AE), and for whom a survival status at the end of the trial cannot be determined will be 
classified as ‚Äúlost to follow-up‚Äù as the reason for discontinuation.  Survival status can be 
determined from a variety of sources, either by [CONTACT_788495] (ie, death certificate, medical records, public records, statement by a family 
member or primary care physician) or acceptable documentation for life (ie, direct 
contact [CONTACT_1155], medical records, successful telephone contact [CONTACT_1155], 
statement by a family member or primary care physician, or public records).
The site will make [ADDRESS_1085630] via certified mail or an alternative similar method, where appropriate, before 
assigning a ‚Äúlost to follow-up‚Äù status.
3.[ADDRESS_1085631] Compliance 
Responsible trial personnel will dispense the IMP (ie, brexpi[INVESTIGATOR_4253], aripi[INVESTIGATOR_4253], and 
placebo) to subjects.  Accountability and compliance verification should be documented 
in the subject‚Äôs trial records.  Subjects must be counseled on the importance of taking the 
IMP as directed at all trial visits.  If poor compliance continues after counseling (eg, 
multiple missed doses resulting in less than 80% overall compliance), discontinuation of 
the subject from the trial should be considered.
3.13 Protocol Deviations
This trial is intended to be conducted as described in this protocol.  In the event of a 
significant deviation from the protocol due to an emergency, accident, or mistake (eg, 
violation of informed consent process, IMP dispensing or subject dosing error, treatment 
assignment error, subject enrolled in violation of eligibility criteria or concomitant 
medication criteria), the investigator or designee will contact [CONTACT_788496].  The investigator and sponsor will come as quickly as Clinical Study Report 331-10-[ADDRESS_1085632]‚Äôs best medical interests should guide the investigator in the management of 
conditions that are pre-existing or that develop during the trial (intercurrent illness or 
AEs).  The investigator should examine the acceptability of all concomitant medications 
not explicitly prohibited.  In order to ensure that appropriate concomitant therapy is 
administered, it is essential that subjects be instructed not to take any medications (either 
self-administered non-prescription drugs or prescription therapy prescribed by [CONTACT_3213]) without prior consultation with the investigator.  All trial personnel should be 
familiar with the content of the IB for brexpi[INVESTIGATOR_788454]‚Äôs 
condition adequately and select appropriate concomitant medications, if needed.
4.2.2 Non-therapy Precautions and Restrictions
[IP_ADDRESS] Precautions
Subjects should not undergo any elective medical procedure without prior consultation 
with the investigator.  An elective procedure (eg. minor surgery, dental surgery, 
orthopedic surgery) that might require hospi[INVESTIGATOR_788455].
[IP_ADDRESS] Restrictions
With the exception of inpatient group therapy, new-onset psychotherapy is prohibited 
during the trial.  In other words, except for inpatient group therapy, subjects may only 
receive psychotherapy (eg, individual, group, marriage, or family therapy) if they have 
been participating in the therapy regularly (ie, weekly) for at least 6 weeks (42 days) prior 
to screening and commit to maintain their participation during the course of the trial at 
the current frequency or unless permission is obtained from the medical monitor.
Consumption of grapefruit, grapefruit products, Seville oranges, or Seville orange 
products within [ADDRESS_1085633] and unintended 
response to an IMP related to any dose administered.
A suspected adverse reaction is any AE for which there is a reasonable possibility that the 
IMP caused the AE.  For the purpose of IND safety reporting, ‚Äúreasonable possibility‚Äù 
means there is evidence to suggest a causal relationship between the IMP and the AE.  
Suspected adverse reaction implies a lesser degree of certainty about causality.
An SAE includes any event that results in any of the following outcomes:
‚Ä¢Death
‚Ä¢Life-threatening; ie, the subject was, in the opi[INVESTIGATOR_871], at immediate 
risk of death from the event as it occurred.  It does not include an event that, had it 
occurred in a more severe form, might have caused death.
‚Ä¢Persistent or significant incapacity/disability or substantial disruption of the ability to 
conduct normal life functions.
‚Ä¢Requires inpatient hospi[INVESTIGATOR_34908].
‚Ä¢Hospi[INVESTIGATOR_444437]; whenever possible the 
reason for the hospi[INVESTIGATOR_92657].
‚Ä¢Hospi[INVESTIGATOR_92658] (ie, those 
required for reasons of convenience or other non-medical need) are not 
considered SAEs.
‚Ä¢Congenital anomaly/birth defect.
‚Ä¢Other medically significant events that, based upon appropriate medical judgment, 
may jeopardize the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed above; eg, allergic bronchospasm requiring 
intensive treatment in an emergency room or home, blood dyscrasias or convulsions 
that do not result in hospi[INVESTIGATOR_059], or the development of drug dependency or drug 
abuse.
Nonserious adverse events are all AEs that do not meet the criteria for an SAE.Clinical Study Report 331-10-[ADDRESS_1085634] be indicated on the AE screen 
in eSource.  Examples of AEs that are considered EPS include, but are not limited to:  
generalized rigidity, hyperkinesia, bradykinesia, akinesia, dystonia, hypertonia, akathisia, 
tremor, flexed posture, involuntary muscle contractions, athetosis, and chorea.  If a 
subject is experiencing [ADDRESS_1085635] be 
entered as ‚Äúextrapyramidal syndrome‚Äù on the AE screen in eSource instead of the 
individual symptoms.  Permitted treatments for EPS are described in Section 4.2.1.
Immediately Reportable Event (IRE):
‚Ä¢Any SAE.
‚Ä¢Any AE related to occupational exposure.
‚Ä¢Potential serious hepatotoxicity cases (any increase of AST or ALT ‚â• 3 times the 
upper normal limit or screening value with an increase in total bilirubin ‚â• 2 times 
the upper normal limit or screening value) 
‚Ä¢Pregnancies are also defined as IREs.  Although normal pregnancy is not an AE, 
it will mandate IMP discontinuation and must be reported on an IRE form to the 
sponsor.  Pregnancy will only be documented on the AE screen in eSource if there 
is an abnormality or complication.
Clinical Laboratory Test Value Changes:  It is the investigator‚Äôs responsibility to review 
the results of all laboratory tests as they become available.  This review will be 
documented by [CONTACT_093]‚Äôs dated signature [CONTACT_444495].  For each 
abnormal laboratory test result, the investigator needs to ascertain if this is an abnormal 
(ie, clinically significant) change from baseline for that individual subject.  This 
determination, however, does not necessarily need to be made the first time an abnormal 
value is observed.  The investigator may repeat the laboratory test or request additional 
tests to verify the results of the original laboratory tests.  If this laboratory value is 
considered medically relevant by [CONTACT_093] (subject is symptomatic, requiring 
corrective treatment or further evaluation), or if the laboratory value leads to 
discontinuation, or fulfills a seriousness criterion, this is considered an AE. 
Severity:  Adverse events will be graded on a 3-point scale and reported as indicated in 
eSource.  The intensity of an adverse experience is defined as follows:
1 = Mild: Discomfort noticed, but no disruption to daily activity.
2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity.
3 = Severe: Inability to work or perform normal daily activity.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
74
Protocol 331-10-234
Confidential - Proprietary Information 74 Version 5.0, 05 Jul 2022IMP Causality:  Assessment of causal relationship of an AE to the use of the IMP is 
defined as follows:
Related: There is a reasonable possibility of a temporal and causal 
relationship between the IMP and the AE.
Not Related: There is no temporal or causal relationship between the IMP and 
the AE.
5.2 Eliciting and Reporting Adverse Events
The investigator will periodically assess subjects for the occurrence of AEs.  To avoid 
bias in eliciting AEs, subjects should be asked the non-leading question:  ‚ÄúHow have you 
felt since your last visit?‚Äù  All AEs (serious and nonserious) reported by [CONTACT_788497].  The AE 
collection is to begin after a subject has signed the ICF.  
Use medical terminology in AE reporting.  Adverse events should be reported as a single 
unifying diagnosis whenever possible or, in the absence of a unifying diagnosis, as 
individual signs or symptoms.  Exacerbation or disease progression should be reported as 
an AE only if there are unusual or severe clinical features that were not present, or 
experienced earlier, or not expected based on the course of the condition.  A reported AE 
that undergoes a change in severity, seriousness, or toxicity should be reported as a new 
AE in eSource.
Note:  Normal pregnancy is not an AE and should not be recorded as one in eSource; 
guidelines outlined in Section 5.[ADDRESS_1085636] be completed and sent by e-mail, fax, or overnight courier 
to the sponsor.  (Please note that the IRE form is NOT the AE screen in eSource.) 
Subjects experiencing SAEs should be followed clinically until their health has returned 
to baseline status, or until all parameters have returned to normal or have otherwise been 
explained.  It is expected that the investigator will provide or arrange appropriate Clinical Study Report 331-10-[ADDRESS_1085637]‚Äôs status to 
the sponsor.
5.[ADDRESS_1085638] or ALT that is ‚â• [ADDRESS_1085639], a 
total bilirubin level should also be evaluated.  If the total bilirubin is ‚â• [ADDRESS_1085640] or their partner will take effective measures (ie, double-barrier method) to 
prevent pregnancy during the course of the trial and for [ADDRESS_1085641] is sterile (ie, females who have had a bilateral oophorectomy or 
hysterectomy or who have been postmenopausal for at least 12 consecutive months; or 
men who have had a bilateral orchidectomy) or remains abstinent, [ADDRESS_1085642] be used:  vasectomy, tubal ligation, vaginal diaphragm, intrauterine 
device, birth control pi[INVESTIGATOR_3353], birth control depot injection, birth control implant, birth control 
patch, condom with spermicide, or sponge with spermicide.  Any single method of birth 
control, including vasectomy and tubal ligation, may fail, leading to pregnancy.  The 
contraceptive method will be documented at each trial visit.
Before enrolling females in this clinical trial, investigators must review the below 
guidelines about trial participation with all females.  The topi[INVESTIGATOR_78609]:
‚Ä¢General information
‚Ä¢Informed consent form
‚Ä¢Pregnancy prevention information
‚Ä¢Drug interactions with hormonal contraceptives
‚Ä¢Contraceptives in current use
‚Ä¢Guidelines for the follow up of a reported pregnancy
Before trial enrollment, females must be advised of the importance of avoiding 
pregnancy during trial participation and the potential risk factors for an unintentional 
pregnancy.  The subject must provide assent or e-sign the electronic ICF stating that the 
above-mentioned risk factors and the consequences were discussed with her. 
A urine or serum pregnancy test for human chorionic gonadotropin will be performed at 
screening on all female subjects.  At any time during the trial if a urine test is performed 
and is positive, the investigator will follow up with a confirmatory serum test.Clinical Study Report 331-10-[ADDRESS_1085643] they might be pregnant (eg, missed or late menstrual cycle).
If a subject is suspected to be pregnant before she receives IMP, the IMP administration 
must be withheld until the results of serum pregnancy tests are available.  If the 
pregnancy is confirmed, the subject must not receive the IMP and must not be enrolled in 
the trial.  If pregnancy is suspected while the subject is taking IMP, the IMP must be 
withheld immediately (if reasonable, taking into consideration any potential withdrawal 
risks) until the result of the pregnancy test is known.  If pregnancy is confirmed, the IMP 
will be permanently discontinued in an appropriate manner (eg, dose tapering if 
necessary for subject safety) and the subject will be withdrawn from the trial.  Exceptions 
to trial discontinuation may be considered for life-threatening conditions only after 
consultations with the Clinical Safety and Pharmacovigilance department (see the cover 
page of this protocol for contact [CONTACT_3031]).
The investigator must immediately notify the sponsor of any pregnancy associated with 
IMP exposure during the trial and for [ADDRESS_1085644] 
Pregnancy Surveillance Form(s) for monitoring the outcome of the pregnancy. 
Protocol-required procedures for trial discontinuation and follow up must be performed 
on the subject unless contraindicated by [CONTACT_8663] (eg, x-ray studies).  Other appropriate 
pregnancy follow-up procedures should be considered, if indicated.  In addition, the 
investigator must report to the sponsor, on appropriate Pregnancy Surveillance Form(s), 
follow-up information regarding the course of the pregnancy, including perinatal and 
neonatal outcome.  Infants will be followed for a minimum of [ADDRESS_1085645] the sponsor/Clinical Research Organization 
(CRO) medical advisor to discuss their rationale for unblinding.  However, to prevent 
delays to the investigator or medical personnel responding to a potentially emergent 
situation, unblinding of IMP will not be dependent upon the investigator receiving 
approval from the sponsor/CRO medical advisor (ie, the investigator will be able to 
obtain the code break information independent of the sponsor/CRO medical advisor).  
The investigator must contact [CONTACT_456]/CRO medical advisor by [CONTACT_16062] e-mail 
with an explanation of the need for opening the treatment assignment code within Clinical Study Report 331-10-[ADDRESS_1085646] be notified immediately (see the cover page of this 
protocol for contact [CONTACT_3031]).  Documentation of breaking the blind should be 
recorded in the subject‚Äôs medical record with the date and time the blind was broken and 
the names of the personnel involved.  Once the blind is broken for a subject, that subject 
may not reinitiate treatment with the IMP.
5.[ADDRESS_1085647] be recorded on the 
AE screen in eSource with the current status noted.  For this trial, information on AEs 
will be followed for up to 21 (¬± 2) days after the last dose of IMP has been administered.  
All nonserious events that are ongoing at the last scheduled contact [CONTACT_788498].  For any AE having been identified throughout the trial, during 
analysis, additional relevant medical history information may be requested to further 
ascertain causality (including, but not limited to, information such as risk-related 
behavior, family history and occupation).
5.7.2 Follow-up of Serious Adverse Events
This trial requires that subjects be actively monitored for SAEs up to 21 (¬± 2) days after 
the last dose of IMP is administered and as described below in Section 5.7.3.
Serious adverse events that are identified or ongoing at the last scheduled contact [CONTACT_788499] 5.3.  This may i nclude unresolved previously 
reported SAEs, or new SAEs.  The investigator will follow SAEs until the events are 
resolved, stabilized, or the subject is lost to follow-up.  Resolution means that the subject 
has returned to the baseline state of health and stabilized means that the investigator does 
not expect any further improvement or worsening of the subject‚Äôs condition.  The 
investigator will continue to report any significant follow-up information to the sponsor 
up to the point the event has been resolved.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
78
Protocol 331-10-234
Confidential - Proprietary Information 79 Version 5.0, 05 Jul 2022The core dataset for all efficacy analyses is based on the intent-to-treat (ITT) population, 
which is defined in the Efficacy Sample above.  The observed case (OC) dataset will be 
used in the primary analysis of efficacy endpoints.  As described below, in order to 
handle missing data and restrictions imposed by [CONTACT_788500] (eg, change 
from baseline analysis), datasets derived from the ITT population will be used for the 
efficacy analyses.
7.[ADDRESS_1085648].
In general, missing data will be handled by [CONTACT_788501] 
(MMRM) methodology based on all data from protocol-specified visits in the ITT 
population under the assumption of missing at random (MAR), which is a reasonable 
assumption in longitudinal clinical trials with psychiatric drugs.  However, the possibility 
of ‚Äúmissing not at random‚Äù (MNAR) data can never be ruled out.  As sensitivity analyses, 
multiple imputation (MI) will be used to explore data missing mechanisms of MNAR and 
investigate the response profile of dropout reasons.  Details of these exploratory analyses 
will be provided in the Statistical Analysis Plan (SAP).
The OC dataset will consist of actual observations recorded at each visit during 
double-blind treatment and no missing data will be imputed.  An MMRM will be 
performed on the OC dataset.
In order to assess sensitivity of results due to missing data, a last observation carried 
forward (LOCF) analysis will be performed as a sensitivity analysis.  In contrast to the 
OC dataset, the LOCF dataset will include data recorded at a scheduled visit, ie, all OC 
data, or, if no observation is recorded at that visit, data carried forward from the 
previously scheduled visit.  Baseline data will not be carried forward to impute missing 
values for the LOCF dataset.Clinical Study Report 331-10-[ADDRESS_1085649] in the protocol uses the 
hypothetical strategy specified in the International Council for Harmonisation (ICH) E9 
Addendum.  The objective of the primary analysis is to compare the efficacy of 
brexpi[INVESTIGATOR_788456].  The estimand, or target 
of estimation, following this hypothetical strategy is the treatment effect seen, assuming 
that no withdrawals occurred.  Subjects who withdraw from IMP treatment either could 
have lost their treatment effect had the subjects not taken any other treatment after 
withdrawal or could have had their treatment effect masked had the subjects taken other 
treatment after withdrawal.  This would mean that any observations made after subjects 
stop IMP will most likely not contribute relevant information about the treatment effect 
of the drug. Due to this strategy, the last efficacy assessment after premature trial 
discontinuation will be done only once at the ET Visit.  Every effort will be made to 
complete all of the ET evaluations prior to administering any additional medications for 
the treatment of schizophrenia or other prohibited medications.  In the case of terminal or 
lost to follow-up events, no ET evaluations would be expected, and only scheduled 
assessments would be performed before such an event occurred.
The primary estimand for this trial is defined by [CONTACT_13673]:
‚Ä¢Target Population: Adolescent subjects 13 to 17 years of age with schizophrenia who 
met the protocol-defined inclusion/exclusion criteria and were qualified for the 
Efficacy Sample
‚Ä¢Endpoint: Change from Baseline to Week 6 in the PANSS Total Score
‚Ä¢Intercurrent Events: Refers to premature treatment discontinuation (ie, early dropout) 
prior to Week 6 attributable to adverse events, lack of efficacy, withdrawal of 
consent/assent, or any other causes
‚Ä¢Measure of Intervention Effect:  Difference in endpoint means between the 
brexpi[INVESTIGATOR_788457].
In this hypothetical strategy, the event of withdrawing IMP is considered MAR, and the 
primary endpoint of the trial could be considered as a combination of the responses of on 
treatment completers at Week [ADDRESS_1085650] is brexpi[INVESTIGATOR_4253] 2‚Äì[ADDRESS_1085651] covariates of baseline and 
baseline by [CONTACT_788502] 1 to 
Week 6 in PANSS Total Score based on all available data (OC dataset).  The data will be 
modeled using an unstructured variance covariance matrix for the within subject 
variation.  A statistical test of the least squares (LS) mean differences at Week 6 of the 
MMRM analysis will serve as the analysis of the primary endpoint.  The Efficacy Sample 
will be used in the analysis of the primary endpoint.  The comparison will be tested at a 
significance level of 0.05 (2-side).
In case there is a convergence problem with the MMRM model with the unstructured 
variance covariance matrix, the following structures other than unstructured will be used 
in order of 1) heterogeneous toeplitz, 2) heterogeneous autoregressive of order 1, and 
3) heterogeneous compound symmetry, and the first (co)variance structure converging to 
the best fit will be used as the primary analysis.  If a structured covariance has to be used, 
the ‚Äúsandwich‚Äù estimator of the standard error of the fixed effects parameters will be used 
in order to deal with possible model misspecification of the covariance matrix.  
In order to explore the robustness of the primary analysis based on the MAR assumption, 
sensitivity analysis of the primary efficacy endpoint under the MNAR assumption will be 
conducted, using a pattern-mixture model. 
Additional details, including pooling of small trial sites are provided in the SAP. 
7.4.2 Secondary Endpoint Analysis
For all continuous secondary endpoints (CGI-S, CGI-I, CGAS, PANSS Positive Subscale 
score, and PANSS Negative Subscale score), an MMRM analysis with factors of 
treatment, trial site, visit, treatment by [CONTACT_23259], and baseline and baseline by [CONTACT_788503] (OC dataset).  The CGI-I 
score at endpoint will be analyzed at the last visit using the Cochran-Mantel-Haenszel Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
82
Protocol 331-10-234
Confidential - Proprietary Information 82 Version 5.0, 05 Jul 2022(CMH) row mean scores differ test controlling for trial site.  The CMH general 
association test controlling for trial site will be applied to the analysis of percentage of 
subjects achieving response and remission by [CONTACT_788504], for the Efficacy 
Sample.  Response is defined as reduction of ‚â• 30% from baseline in PANSS Total Score 
or CGI-I score of 1 or 2.  Remission is defined as a score of ‚â§ 3 on each of the following 
specific PANSS items: delusions (P1), unusual thought content (G9), hallucinatory 
behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted 
affect (N1), passive/apathetic social withdrawal (N4), and lack of spontaneity and 
conversation flow (N6). 
7.4.3 Exploratory Endpoint Analysis
The change in the P-Q-LES-Q total score (ie, 14 items) will be summarized using an 
MMRM analysis with factors of treatment, trial site, visit, treatment by [CONTACT_23259], 
and baseline and baseline by [CONTACT_487463], with an unstructured variance 
covariance structure.  All available data (OC dataset) will be applied in the model.  
Additionally, change from baseline in the overall score of P-Q-LES-Q will be 
summarized using the CMH row mean scores differ test controlling for trial site.
Hospi[INVESTIGATOR_788458] 2 categories:  hospi[INVESTIGATOR_788459].
Additional details for exploratory endpoint analysis are provided in the SAP.
7.4.4 Interim Analysis
No formal unblinded interim analysis is planned for this trial.
7.5 Analysis of Demographic and Baseline Characteristics
Demographic characteristics, disease severity, and psychiatric and medical history at 
(predose) baseline will be summarized by [CONTACT_9086], eg, proportion, mean, 
median, SD, and minimum and maximum values.  These summary statistics will be 
reviewed to identify any potential lack of balance between the treatment groups in the 
Randomized Sample.
7.[ADDRESS_1085652] circumference, and body mass index.  In addition, data from 
the following safety scales will be evaluated:  SAS, AIMS, BARS, and C-SSRS.  The 
safety analysis will be conducted based on the Safety Sample which is defined in Clinical Study Report 331-10-[ADDRESS_1085653] dose of IMP, unless specified otherwise.  Details of the 
safety analysis will be provided in the SAP.
7.6.1 Adverse Events
All AEs will be coded by [CONTACT_788505] (MedDRA) preferred term.  The incidence of the following events will be 
summarized by [CONTACT_1570]:
‚Ä¢TEAEs
‚Ä¢TEAEs by [CONTACT_926]
‚Ä¢TEAEs potentially causally related to the IMP
‚Ä¢TEAEs with an outcome of death
‚Ä¢Serious TEAEs
‚Ä¢TEAEs leading to discontinuations of the IMP
The above summaries will also be prepared for TEAEs potentially causally related to the 
IMP.
7.6.[ADDRESS_1085654] of IMP (brexpi[INVESTIGATOR_4253], 
aripi[INVESTIGATOR_4253], and placebo) received, dispensed, administered, and returned.
8.[ADDRESS_1085655] 
shippi[INVESTIGATOR_7788].  Returned supplies should be in the original containers (eg, subject 
kits).  The assigned trial monitor will facilitate the return or destruction of used IMP 
containers, unused IMP, and partially used IMP.
8.[ADDRESS_1085656] quality complaint (PQC) is any written, electronic, or verbal communication 
by a healthcare professional, consumer, subject, medical representative, Competent 
Authority, regulatory agency, partner, affiliate or other third party that alleges 
deficiencies or dissatisfaction related to identity, quality, labeling, packaging, reliability, 
safety, durability, tampering, counterfeiting, theft, effectiveness or performance of a drug 
product or medical device after it is released for distribution.  Examples include, but are 
not limited to, communications involving:
‚Ä¢Failure/malfunction of a product to meet any of its specifications
‚Ä¢Incorrect or missing labeling
‚Ä¢Packaging issues (eg, damaged, dirty, crushed, missing product)
‚Ä¢Blister defects (eg, missing, empty blisters)Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
86
Protocol 331-10-234
Confidential - Proprietary Information 86 Version 5.0, 05 Jul 2022‚Ä¢Bottle defects (eg, under/over-fill, no safety seal)
‚Ä¢Vial defects
‚Ä¢Product defect (eg, odor, chipped, broken, embossing illegible)
‚Ä¢Loss or theft of product
8.5.[ADDRESS_1085657] all PQCs identified through any means from the 
receipt of the IMP from the sponsor, or sponsor‚Äôs designee, through and including 
reconciliation and up to destruction, including subject dosing.  The investigator or 
designee must notify the sponsor (or sponsor‚Äôs designee) by e-mail or telephone within 
24 hours of becoming aware of the PQC according to the procedure outlined below.
‚Ä¢Online ‚Äì Send information required for reporting purposes (listed below) to 
[EMAIL_15031].
‚Ä¢Telephone - Rocky Mountain Call Center at [PHONE_16438].
Identification of a PQC by [CONTACT_35084], who 
should then follow one of the reporting mechanisms above.
8.5.2 Information Required for Reporting Purposes
‚Ä¢Description of complaint
‚Ä¢Reporter identification (eg, subject, investigator, site, etc.)
‚Ä¢Reporter contact [CONTACT_3031] (eg, address, telephone number, e-mail address)
‚Ä¢ID of material (product/compound name, coding)
‚Ä¢Clinical protocol reference (number or trial name)
‚Ä¢Dosage form/strength (if known)
‚Ä¢Pi[INVESTIGATOR_499] (if available)
‚Ä¢Availability for return
8.5.[ADDRESS_1085658] that a complaint sample for a 
dispensed kit has been forwarded to the sponsor for complaint investigation.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
87
Protocol 331-10-234
Confidential - Proprietary Information 87 Version 5.0, 05 Jul [ZIP_CODE].5.4 Assessment/Evaluation
Assessment and evaluation of PQCs will be handled by [CONTACT_456].
[ADDRESS_1085659] inspection by [CONTACT_92718].
Investigator(s)/institution(s) will permit trial-related monitoring, audits, IRB/IEC review, 
and regulatory inspection(s) by [CONTACT_20618]/documents by 
[CONTACT_331690].  In all cases, subject confidentiality must be 
maintained in accordance with local regulatory requirements.
9.2 Data Collection
Source document and source data will be captured electronically in this trial and will 
meet the same fundamental elements of data quality (eg, attributable, legible, 
contemporaneous, original, and accurate) as paper records.  These data will be collected 
into a system that is fully validated.  Changes to the data will be captured by [CONTACT_740900].
The trial site will be given a tablet to directly record subject data and clinical 
observations on electronic forms.  Designated trial site staff will not be given access to 
the system until they have been appropriately trained.  Information to be originally 
captured and reviewed electronically shall include details of the subject visit and the 
protocol-required assessments performed as a part of these visits, medical history, AEs, 
and concomitant medications.  Because this trial is using an electronic source record as 
the original point of data capture, there is no additional data entry step for the site for data 
collected directly into the application - rather, the electronic source record directly 
populates the trial database.
Some data may be captured via paper and then entered into the eSource.  These and any 
other data treated in this manner will be source data verified by [CONTACT_788506], and the location of the source data (ie, eSource, paper, or a local electronic 
system) will be documented before the trial start.  Any changes to information in paper Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
88
Protocol 331-10-234
Confidential - Proprietary Information 88 Version 5.0, 05 Jul 2022source documents will be initialed and dated on the day the change is made by a trial site 
staff member authorized to make the change.  Changes will be made by [CONTACT_2724] a single 
line through erroneous data (so as not to obliterate the original data), and clearly entering 
the correct data (eg, wrong data right data).  If the reason for the change is not apparent, a 
brief explanation for the change will be written in the source documentation by [CONTACT_984].
Another exception will be safety laboratory data, where the official source documentation 
will be considered the report issued by [CONTACT_444491].
Remote monitoring of the original electronic source record will take place, however 
on-site monitoring inspections will continue to take place in order to review data entry 
source documentation directly captured on paper and transcribed into the system, to 
ensure protocol adherence, to assess site operational capabilities and to perform other 
monitoring activities that cannot be performed remotely.  
At the end of the trial, the investigator must certify that the data entered into the eSource 
application are complete and accurate.  After database lock, the investigator will receive 
an electronic copy of the subject data. 
9.3 File Management at the Trial Site
The investigator will ensure that the trial site file is maintained in accordance with 
Section 8 of the ICH GCP Guideline E6 and as required by [CONTACT_13762].  
The investigator/institution will take measures to prevent accidental or premature 
destruction of these documents.  Per regulatory guidelines, sites must retain any 
documents that are uploaded to eSource.
9.[ADDRESS_1085660] of the following 
3 periods:
‚Ä¢A period of at least 2 years after the date on which approval to market the drug is 
obtained (or if IMP development is discontinued, the date regulatory authorities were 
notified of discontinuation); OR
‚Ä¢A period of at least 3 years after the sponsor notifies the investigator that the final 
report has been filed with regulatory authorities.
‚Ä¢Longer, region-specific storage requirements, if applicable.Clinical Study Report 331-10-[ADDRESS_1085661] not dispose of any records relevant to this trial without either 
(1) written permission from the sponsor or (2) provision of an opportunity for sponsor to 
collect such records.  The investigator will be responsible to maintain adequate and 
accurate electronic or hard copy source documents of all observations and data generated 
during this trial including any data clarification forms received from the sponsor.  Such 
documentation is subject to inspection by [CONTACT_331692].  
If the investigator withdraws from the trial (eg, due to relocation or retirement), all 
trial-related records should be transferred to a mutually agreed-upon designee within a 
sponsor-specified timeframe.  Notice of such transfer will be given to the sponsor in 
writing.
10 Quality Control and Quality Assurance 
10.1 Monitoring
The sponsor has ethical, legal, and scientific obligations to follow this trial in accordance 
with established research principles, the ICH E6 GCP:  Consolidated Guidance, and 
applicable regulatory requirements and local laws.  As part of a concerted effort to fulfill 
these obligations (maintain current personal knowledge of the progress of the trial), the 
sponsor‚Äôs monitors will visit the site during the trial, as well as communicate frequently 
via telephone, e-mail, and written communications.  In addition, all investigators and 
clinical site personnel will undergo initial and ongoing training for this particular trial, 
and this training will be clearly documented.
10.2 Auditing
The sponsor‚Äôs Quality Assurance Unit (or representative) may conduct trial site audits.  
Audits will include, but are not limited to, IMP supply, presence of required documents, 
the informed consent process, and comparison of eSource with source documents.  The 
investigator agrees to participate with audits.
Regulatory authorities may inspect the investigator site during or after the trial.  The 
investigator will cooperate with such inspections and will contact [CONTACT_331687].
[ADDRESS_1085662] be conducted in compliance with the protocol, FDA regulations, ICH GCP 
Guideline (E6), international ethical principles derived from the Declaration of Helsinki 
and Council for International Organizations of Medical Science (CIOMS) guidelines, and 
applicable local laws and regulations.  Each trial site will seek approval/favorable opi[INVESTIGATOR_788460] 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
90
Protocol 331-10-234
Confidential - Proprietary Information 90 Version 5.0, 05 Jul 2022by [CONTACT_35090], and the investigator will provide 
that documentation to the sponsor.  The IRB/IEC will evaluate the ethical, scientific, and 
medical appropriateness of the trial.  Further, in preparing and using screens in eSource, 
the investigator, subinvestigator, and their staff will take measures to ensure adequate 
care in protecting subject privacy.  To this end, a subject number and subject 
identification code will be used to identify each subject.
Financial aspects, subject insurance and the publication policy for the trial will be 
documented in the agreement between the sponsor and the investigator.
12 Confidentiality
All information generated in this trial will be considered confidential and will not be 
disclosed to anyone not directly concerned with the trial without the sponsor‚Äôs prior 
written permission.  Subject confidentiality requirements of the region(s) where the trial 
is conducted will be met.  However, authorized regulatory officials and sponsor personnel 
(or their representatives) may be allowed full access to inspect and copy the records, 
consistent with local requirements.  All IMPs, subject bodily fluids, or other materials 
collected shall be used solely in accordance with this protocol, unless otherwise agreed to 
in writing by [CONTACT_456].
Subjects will be identified only by [CONTACT_772998].  If further subject 
identification is required, subjects‚Äô full names may be made known to a regulatory 
agency or other authorized officials if necessary, subject to local regulations.
13 Amendment Policy
The investigator will not make any changes to this protocol without the sponsor‚Äôs prior 
written consent and subsequent approval/favorable opi[INVESTIGATOR_1686]/IEC.  Any 
permanent change to the protocol, whether an overall change or a change for specific trial 
site(s), must be handled as a protocol amendment.  Any amendment will be written by [CONTACT_103].  Each amendment will be submitted to the IRB/IEC, as required by [CONTACT_13125].  Except for ‚Äúadministrative‚Äù or ‚Äúnon-substantial‚Äù amendments, investigators 
will wait for IRB/IEC approval/favorable opi[INVESTIGATOR_444443](s).  Administrative amendments are defined as having no effect 
on the safety of subjects, conduct or management of the trial, trial design, or the quality 
or safety of IMP(s) used in the trial.  A protocol change intended to eliminate an apparent 
immediate hazard to subjects should be implemented immediately after agreement by [CONTACT_331694], followed by [CONTACT_1744]/IEC notification within local applicable Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
91
Protocol 331-10-234
Confidential - Proprietary Information 91 Version 5.0, 05 Jul 2022timelines.  The sponsor will submit protocol amendments to the applicable regulatory 
agencies within local applicable timelines.
When the IRB/IEC, investigators, or the sponsor conclude that the protocol amendment 
substantially alters the trial design or increases the potential risk to the subject, the 
currently approved written ICF will require similar modification.  In such cases, after 
approval/favorable opi[INVESTIGATOR_331644]/IEC, repeat written informed 
consent will be obtained from subjects enrolled in the trial before expecting continued 
participation and before the amendment-specified changes in the trial are implemented.
[ADDRESS_1085663] of this trial 
will be based on International Committee of Medical Journal Editors (ICMJE) authorship 
criteria (http://www.icmje.org/recommendations).  According to ICMJE guidelines, one 
may be considered an author only if the following criteria are met:
1. Substantial contributions to the conception or design of the work; or the 
acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved.
All authors must meet the above criteria, and all who qualify for authorship based on the 
above criteria should be listed as authors.
Investigators or other trial participants who do not qualify for authorship may be 
acknowledged in publications resulting from the trial.  By [CONTACT_92726], investigators or other trial participants consent to such acknowledgement in any 
publications resulting from its conduct.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
92
Protocol 331-10-234
Confidential - Proprietary Information 92 Version 5.0, 05 Jul 202215 References
1Messias E, Chen CY, Eaton WW. Epi[INVESTIGATOR_788461]: Review of 
findings and myths. Psychiatr Clin North Am. 2007;30(3):323-338.
2McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of 
incidence, prevalence, and mortality. Epi[INVESTIGATOR_19274]. 2008;30:67-76.
3van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635-645.
4American Diabetes Association, American Psychiatric Association, American 
Association of Clinical Endocrinologists, North American Association for the Study 
of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity 
and Diabetes. J Clin Psychiatry. 2004;65(2):267-272.
5David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapi[INVESTIGATOR_050], risperidone, 
and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 
2000;22(9):1085-1096.
6Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. 
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with 
clozapi[INVESTIGATOR_050], olanzapi[INVESTIGATOR_050], risperidone, or haloperidol. J Clin Psychiatry. 2004;65(1):57-
61.
7Hollis C. Adult outcomes of child- and adolescent-onset schizophrenia: Diagnostic 
stability and predictive validity. Am J Psychiatry. 2000;157(10):1652-1659.
8Sikich L. Efficacy of atypi[INVESTIGATOR_788462]-onset schizophrenia and other 
psychotic disorders. J Clin Psychiatry. 2008;69(Suppl 4):21-25.
9Lay B, Blanz B, Hartmann M, Schmidt MH. The psychosocial outcome of 
adolescent-onset schizophrenia: A 12-year followup. Schizophr Bull. 2000;26(4):801-
816.
10Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, et al. 
Double-blind maintenance safety and effectiveness findings from the treatment of 
early-onset schizophrenia spectrum (TEOSS) study. J Am Acad Child Adolesc 
Psychiatry. 2010;49(6):583-594.
11Otsuka Pharmaceutical Co, Ltd., Otsuka Pharmaceutical Development & 
Commercialization, Inc., H. Lundbeck A/S. REXULTI¬Æ (brexpi[INVESTIGATOR_4253]) 
Investigator's Brochure, Edition 12. Otsuka Report, issued 18 Aug 2016.
12Brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE]) Investigator's Brochure, Otsuka Pharmaceutical 
Development & Commercialization, Inc. Version No. 9, 09 Sep 2013.
13International Conference for Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use. Guideline For Good Clinical 
Practice: E6(R1). Geneva, Switzerland: International Conference on Harmonisation; 
1996.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
93
Protocol 331-10-234
Confidential - Proprietary Information 93 Version 5.0, 05 Jul 202214Kay SR, Fiszbein A, Opler LA. Positive and Negative Syndrome Scale (PANSS) 
Technical Manual. North Tonawanda, NY: Multi-Health Systems; 2006.
15Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A children's 
global assessment scale (CGAS). Arch Gen Psychiatry. 1983;40(11):1228-1231.
16Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of 
Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National 
Institute of Mental Health; 1976.
17The Practical Guide: Identification, evaluation, and treatment of overweight and 
obesity in adults. Developed by [CONTACT_628589], Lung 
and Blood Institute. North American Association for the Study of Obesity. NIH 
Publication Number 00-4084, October 2000.
18Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta 
Psychiatr Scand Suppl. 1970;212(Suppl 44):S11-19.
19Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-
676.
20Kaufman J, Birmaher B, Brent D, Rao U, Ryan N. Kiddie-Sads-Present and Lifetime 
Version (K-SADS-PL). Version 1.[ADDRESS_1085664] 1996 ed. Pi[INVESTIGATOR_9109], PA:  Department of 
Psychiatry, University of Pi[INVESTIGATOR_99601]; 1996.
21US Food and Drug Administration. Clinicaltrial.gov register. Efficacy and Safety of 
Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With 
Schizophrenia. Available at: https://www.clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]. 
Assessed on 08 March 2022.
22European Medicines Agency/[ZIP_CODE]/2021. Committee for Medicinal Products for 
Human Use (CHMP). Latuda Assessment Report. 23 July 2020. Procedure No. 
EMEA/H/C/002713/II/0029.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
94
Protocol 331-10-234
Confidential - Proprietary Information 94 Version 5.0, 05 Jul 2022Appendix 1 Criteria for Identifying Vital Signs of Potential 
Clinical Relevance
Variable Criterion ValueaChange Relative to Baselinea
Heart Rateb > 120 bpm
< 50 bpm‚â• 15 bpm increase
‚â• 15 bpm decrease
Systolic Blood Pressureb > 180 mmHg
< 90 mmHg‚â• 20 mmHg increase
‚â• 20 mmHg decrease
Diastolic Blood Pressureb > 105 mmHg
< 50 mmHg‚â• 15 mmHg increase
‚â• 15 mmHg decrease
Orthostatic Hypotension‚â• 20 mmHg decrease in systolic blood 
pressure and a ‚â• 25 bpm increase in 
heart rate from supi[INVESTIGATOR_657511]/standingNot Applicable
(baseline status not considered)
Weight -‚â• 7% increase
‚â• 7% decrease
aIn order to be identified as potentially clinically relevant, an on-treatment value must meet the 
‚ÄúCriterion Value‚Äù and also represent a change from the subject‚Äôs baseline value of at least the 
magnitude shown in the ‚ÄúChange Relative to Baseline‚Äù column.
bAs defined in ‚ÄúSupplementary Suggestions for Preparing an Integrated Summary of Safety Information 
in an Original NDA Submission and for Organizing Information in Periodic Safety Updates,‚Äù FDA 
Division of Neuropharmacological Drug Products draft (2/27/87).Clinical Study Report 331-10-[ADDRESS_1085665] (SGOT) ‚â• [ADDRESS_1085666]
ALT (SGPT) ‚â• 3 √ó ULN
Alkaline phosphatase ‚â• 3 √ó ULN
LDH ‚â• 3 √ó ULN
BUN ‚â• 30 mg/dL
Creatinine ‚â• 2.0 mg/dL
Uric Acid
Men ‚â• 10.5 mg/dL
Women ‚â• 8.5 mg/dL
Bilirubin (total) ‚â• 2.0 mg/dL
CPK ‚â• 3 √ó ULN
Prolactin > ULN
Hematology
Hematocrit
Men ‚â§ 37 % and decrease of ÔÇ≥ 3 percentage points from Baseline
Women ‚â§ 32 % and decrease of ÔÇ≥ 3 percentage points from Baseline
Hemoglobin
Men ‚â§ 11.5 g/dL
Women ‚â§ 9.5 g/dL
White blood count ‚â§ 2,800/ mm3 or ‚â• 16,000/ mm3
Eosinophils ‚â• 10%
Neutrophils ‚â§ 15%
Absolute neutrophil count ‚â§ 1,000/ mm3
Platelet count ‚â§ 75,000/ mm3 or ‚â• 700,000/ mm3
Urinalysis
Protein Increase of ‚â• 2 units
Glucose Increase of ‚â• 2 units
Casts Increase of ‚â• 2 units
Additional Criteria
Chloride ‚â§ 90 mEq/L or ‚â• 118 mEq/L
Potassium ‚â§ 2.5 mEq/L or ‚â• 6.5 mEq/L
Sodium ‚â§ 126 mEq/L or ‚â• 156 mEq/L
Calcium ‚â§ 8.2 mg/dL or ‚â• 12 mg/dL
Glucose
Fasting ‚â• 100 mg/dL 
Non-Fasting ‚â• 200 mg/dL
Total Cholesterol, Fasting ‚â• 240 mg/dL 
LDL Cholesterol, Fasting ‚â• 160 mg/dL 
HDL Cholesterol, Fasting
Men < 40 mg/dL
Women < 50 mg/dL
Triglycerides, Fasting ‚â• 150 mg/dLClinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
96
Protocol 331-10-234
Confidential - Proprietary Information 96 Version 5.0, 05 Jul 2022Appendix 3 Criteria for Identifying ECG Measurements of Potential 
Clinical Relevance
Variable Criterion ValueaChange Relative to Baselinea
Rate
Tachycardia ‚â• 120 bpm increase of ‚â• 15 bpm
Bradycardia ‚â§ 50 bpm decrease of ‚â• 15 bpm
Rhythm
Sinus tachycardiab ‚â• 120 bpm increase of ‚â• 15 bpm
Sinus bradycardiac ‚â§ 50 bpm decrease of ‚â• 15 bpm
Supraventricular premature beat all not present ÔÉ† present
Ventricular premature beat all not present ÔÉ† present
Supraventricular tachycardia all not present ÔÉ† present
Ventricular tachycardia all not present ÔÉ† present
Atrial fibrillation all not present ÔÉ† present
Atrial flutter all not present ÔÉ† present
Conduction
1¬∞ atrioventricular block PR ‚â• 200 msec increase of ‚â• 50 msec
2¬∞ atrioventricular block all not present ÔÉ† present
3¬∞ atrioventricular block all not present ÔÉ† present
Left bundle-branch block all not present ÔÉ† present
Right bundle-branch block all not present ÔÉ† present
Pre-excitation syndrome all not present ÔÉ† present
Other intraventricular conduction 
blockd QRS ‚â• 120 msec increase of ‚â• 20 msec
Infarction
Acute or subacute all not present ÔÉ† present
Old all not present ÔÉ† present
‚â• [ADDRESS_1085667]/T Morphological
Myocardial Ischemia all not present ÔÉ† present
Symmetrical T-wave inversion all not present ÔÉ† present
Increase in QTc QTcF or QTcN 
‚â• 450 msec for males, 
‚â• [ADDRESS_1085668] meet the 
‚ÄúCriterion Value‚Äù and also represent a change from the subject‚Äôs baseline value of at least the 
magnitude shown in the ‚ÄúChange Relative to Baseline‚Äù column.
bNo current diagnosis of supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial 
flutter, or other rhythm abnormality.
cNo current diagnosis of atrial fibrillation, atrial flutter, or other rhythm abnormality.
dNo current diagnosis of left bundle branch block or right bundle branch block.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
97
Protocol 331-10-234
Confidential - Proprietary Information 97 Version 5.0, 05 Jul 2022Appendix 4 Handling and Shipment of Bioanalytical Samples
Handling of Specimens
Labels should be secured to each storage tube.  Labels should contain the following 
information:  Protocol number; subject number; time point of sample collection; and 
aliquot/matrix (eg, Plasma Aliquot 1 or Plasma Aliquot 2).  All tubes must be labeled 
such that the protocol number, date of collections, and protocol time can be verified.  It is 
important to note the exact time of the blood collection in eSource, not the scheduled 
time for the drawing.
Pharmacokinetic Plasma Samples
Collect PK blood samples using 4-mL draw green-top VacutainerÔÉí evacuated collection 
tubes containing sodium heparin.  After obtaining the blood sample, mix the collection 
tube thoroughly by [CONTACT_788507]/water bath.  
Within 45 minutes of collection, process collection tubes in a refrigerated centrifuge set 
at approximately 2000 x G for 15 minutes at approximately 5ÔÇ∞C ¬± 3¬∞C.  Transfer 
duplicate plasma aliquots of approximately equal volume, using standard laboratory 
technique, into 2 appropriately labeled storage tubes.  Within 90 minutes of collection, 
store both plasma aliquot samples in a freezer set to maintain a temperature 
‚àí70ÔÇ∞C ¬± 10¬∞C.  Specimens must be neatly packed and restrained in an insulated container 
appropriate for dry ice, and organized by [CONTACT_788508].  Completely fill the 
insulated container and avoid air spaces that allow evaporation of the dry ice.  Samples 
must be shipped via an overnight carrier, Monday through Thursday, to the central 
laboratory.  Shipments should not be made on Fridays, Saturdays, or any day prior to a 
holiday.  Plasma Aliquot 1 samples should be shipped preferably on the day of collection 
or else within 1 week of sample collection.  Plasma Aliquot 2 specimens should be 
shipped to the central laboratory using the same procedure, once confirmation is received 
that the Plasma Aliquot 1 specimen was received. 
Pharmacogenomics Sample
Blood samples for pharmacogenomic analysis will be collected into one 6-mL K2EDTA 
VacutainerÔÉí tube.  Each tube should be gently inverted 10 times to ensure proper mixing 
with the anticoagulant.  Samples should be refrigerated in an upright position at 4 ÔÇ∞C for 
at least one day (no longer than 4 days).  The samples should then be stored at -20 ÔÇ∞C or 
below prior to shipment.  If refrigerating is not possible, samples may be frozen directly Clinical Study Report 331-10-[ADDRESS_1085669] be shipped to the central laboratory via an overnight carrier, 
Monday through Thursday, preferably on the day of collection or else within 1 week of 
sample collection.  Shipments should not be made on Fridays, Saturdays, or any day prior 
to a holiday. Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
99
Protocol 331-10-234
Confidential - Proprietary Information 99 Version 5.0, 05 Jul 2022Appendix 5 Positive and Negative Syndrome Scale (PANSS)
This scale consists of symptom constructs, each to be rated on a 7-point scale of severity.
For each symptom, please mark the rating which best describes the patient‚Äôs present 
condition (from 1 = absent to 7 = extreme).
1=absent 2=minimal 3=mild 4=moderate 
5=moderate severe 6=severe 7=extreme
POSITIVE SCALE (P)
1. DELUSIONSBeliefs that are unfounded, unrealistic, and idiosyncratic.
Basis for Rating: thought content expressed during the interview and its 
influence on social relations, and behavior, as reported by [CONTACT_788509].
2.CONCEPTUAL 
DISORGANIZATIONThere is a disorganized thinking process characterized by [CONTACT_788510]-directed 
sequencing disruption (eg circumstantiality, tangentiality, loose associations, non-
sequiturs, gross illogicality, or thought block).
Basis for Rating: cognitive verbal processes observed during the interview.
3.HALLUCINATORY 
BEHAVIORVerbal report or behavior indicate perceptions that are not generated by [CONTACT_788511].  These occurrences may be auditory, visual, olfactory, or somatic.  
Basis for Rating: Verbal report and physical manifestations during the interview 
as well as behavior reports by [CONTACT_788512].
4. EXCITEMENTHyperactivity is reflected in accelerated motor behavior, heightened responsivity 
to stimuli, hypervigilance, or excessive mood lability.
Basis for Rating: behavioral manifestations during the interview, as well as 
behavior reports by [CONTACT_788512].
5. GRANDIOSITYThere exists an exaggerated self-opi[INVESTIGATOR_788463], including delusions of extraordinary abilities, wealth, knowledge, 
fame, power, and moral righteousness.
Basis for Rating: thought content expressed in the interview and its influence on 
behavior as reported by [CONTACT_788512].
6.SUSPI[INVESTIGATOR_285231]/ 
PERSECUTIONUnrealistic or exaggerated ideas of persecution are shown, as reflected in 
guardedness, a distrustful attitude, suspi[INVESTIGATOR_788464], or frank delusions 
that others mean harm.
Basis for Rating: thought content expressed in the interview and its influence on 
behavior as reported by [CONTACT_788512].  
7. HOSTILITYThere are verbal and nonverbal expressions of anger and resentment, including 
sarcasm, passive-aggressive behavior, verbal abuse, and assaultiveness.  
Basis for Rating: interpersonal behavior observed during the interview and 
reports by [CONTACT_788512].  Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
100
Protocol 331-10-234
Confidential - Proprietary Information 100 Version 5.0, 05 Jul 2022NEGATIVE SCALE (N)
1. BLUNTED AFFECTThere is diminished emotional responsiveness characterized by a reduction in 
facial expression, modulation of feelings, and communicative gestures.  
Basis for Rating: observation of the patient‚Äôs affective tone and emotional
responsiveness during the interview.  
2.EMOTIONAL 
WITHDRAWALThere is a lack of interest in, involvement with, and affective commitment to life‚Äôs 
events.  
Basis for Rating: reports of functioning from primary care workers or family, and 
interpersonal behavior observations during the interview.  
3. POOR RAPPORTThere is a lack of interpersonal empathy, a lack of openness in conversation, and 
also a minimal sense of closeness, interest or involvement with the interviewer.  
Poor rapport is evidenced by [CONTACT_788513].  
Basis for Rating: interpersonal behavior during the interview.  
4.PASSIVE/APATHETIC 
AND SOCIAL 
WITHDRAWALDiminished interest and initiative in social interactions due to passivity, apathy, 
anergy, or avolition leading to reduced interpersonal involvements and neglect of 
daily living activities.
Basis for Rating: social behavior reports from primary care workers or family.  
5.DIFFICULTY IN 
ABSTRACT 
THINKINGThe patient shows impairment using the abstract-symbolic thinking mode, as 
demonstrated by [CONTACT_788514], forming generalizations, and 
moving beyond concrete or egocentric thinking in problem-solving tasks.
Basis for Rating: responses to questions on similarities and proverb interpretation, 
and use of concrete vs. abstract mode during the interview.  
6.LACK OF 
SPONTANEITY AND 
FLOW OF 
CONVERSATIONThere is a reduction in the normal flow of communication associated with apathy, 
avolition, defensiveness, or cognitive deficit.  This disruption in normal flow is 
manifested by [CONTACT_788515].
Basis for Rating: cognitive-verbal processes observed during the interview.  
7.STEREOTYPED 
THINKINGThere is decreased fluidity, spontaneity, and flexibility of thinking, as evidenced in 
rigid, repetitious, or barren thought content.
Basis for Rating: cognitive-verbal processes observed during the interview.  Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
101
Protocol 331-10-234
Confidential - Proprietary Information 101 Version 5.0, 05 Jul 2022GENERAL PSYCHOPATHOLOGY SCALE (G)
1.  SOMATIC CONCERN There are physical complaints or beliefs about bodily illness or malfunctions.  
This patient‚Äôs concerns may range from a vague sense of ill being to clear-cut 
delusions of catastrophic physical disease.
Basis for Rating: thought content expressed in the interview.  
2.  ANXIETY There are subjective experiences of nervousness, worry, apprehension, or 
restlessness, ranging from excessive concern about the present or future to 
feelings of panic.  
Basis for Rating: verbal report during the interview and corresponding 
physical manifestations.  
3.  GUILT FEELINGS The patient exhibits a sense of remorse or self-blame for real or imagined 
misdeeds in the past.
Basis for Rating: verbal reports of guilt feelings during the interview and the 
influence of these feelings on the patient‚Äôs attitudes and thoughts.
4.  TENSION There are overt physical manifestation of fear, anxiety, and agitation, such as 
stiffness, tremor, profuse sweating, and restlessness.
Basis for Rating: verbal report attesting to anxiety and, thereupon, the severity 
of physical manifestations of tension observed during the interview.
5.MANNERISM AND 
POSTURING Unnatural movements or posture are shown as characterized by [CONTACT_788516], 
stilted, disorganized, or bizarre appearance.
Basis for Rating: observation of physical manifestations during the interview 
as well as reports from primary care workers or family.
6.  DEPRESSION There are feelings of sadness, discouragement, helplessness, and pessimism.  
Basis for Rating: verbal report of depressed mood during the interview and its 
observed influence on the patient‚Äôs attitude and behavior as reported from 
primary care workers or family.  
7.MOTOR 
RETARDATIONThere is a reduction in motor activity reflected by [CONTACT_788517], diminished responsiveness to stimuli, and reduced 
body tone.  
Basis for Rating: manifestations during the interview as well as reports from 
primary care workers or family.  
8. UNCOOPERATIVENESSThere is an active refusal to comply with the will of significant others, 
including the interviewer, hospi[INVESTIGATOR_33717], or family, perhaps associated with 
distrust, defensiveness, stubbornness, negativism, rejection of authority, 
hostility, or belligerence.  
Basis for Rating: interpersonal behavior observed during the interview as well 
as reports from care workers or family.  
9.UNUSUAL THOUGHT 
CONTENTThinking is characterized by [CONTACT_788518], fantastic, or bizarre ideas, ranging from 
those that are remote or atypi[INVESTIGATOR_788465], illogical, and 
patently absurd.  
Basis for Rating: thought content expressed during the interview.  
10. DISORIENTATIONThere is a lack of awareness of one‚Äôs relationship to one‚Äôs surroundings, 
including persons, places, and time that may be due to confusion or withdrawal.  
Basis for Rating: responses to interview questions on orientation.  
11. POOR ATTENTIONPoor focused alertness is manifested by [CONTACT_788519], distractibility from 
internal and external stimuli, and difficulty in harnessing, sustaining, or shifting 
focus to new stimuli.  Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
102
Protocol 331-10-234
Confidential - Proprietary Information 102 Version 5.0, 05 Jul 2022Basis for Rating: manifestations during the interview.  
12.LACK OF JUDGMENT 
AND INSIGHTThere is an impaired awareness or understanding of one‚Äôs own psychiatric 
condition and life situation.  This impairment is evidenced by [CONTACT_102]‚Äôs 
inability to recognize past or present psychiatric illness or symptoms, denial of 
his or her need for psychiatric hospi[INVESTIGATOR_314556], decisions 
characterized by [CONTACT_788520], and unrealistic 
short-term and long-range planning.  
Basis for Rating: thought content expressed during the interview.  
13.DISTURBANCE OF 
VOLITIONThere is disturbance in the willful initiation, sustenance, and control of one‚Äôs 
thoughts, behavior, movements, and speech.  
Basis for Rating: thought content and behavior manifested during the 
interview.  
14.POOR IMPULSE 
CONTROLThere is disordered regulation and control when acting on inner urges, resulting 
in sudden, unmodulated, arbitrary, or misdirected discharge of tension and 
emotions without concern about the consequences.  
Basis for Rating: the patient‚Äôs behavior during the interview and reports from 
primary care workers or family.  
15. PREOCCUPATION There is absorption with internally generated thoughts and feelings or with 
autistic experiences to the detriment of reality orientation and adaptive 
behavior.  
Basis for Rating: interpersonal behavior observed during the interview.  
16.ACTIVE SOCIAL 
AVOIDANCE There is diminished social involvement associated with unwarranted fear, 
hostility, or distrust.  
Basis for Rating: social functioning reports from primary care workers or 
family.  Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
103
Protocol 331-10-234
Confidential - Proprietary Information 103 Version 5.0, 05 Jul 2022Appendix 6 Children‚Äôs Global Assessment Scale (CGAS)
The C-GAS is a 100-point rating scale measuring psychological, social, and school 
functioning for children aged 6-17.  It was adapted from the Adult Global Assessment 
Scale and is a valid and reliable tool for rating a child‚Äôs general level of functioning on a 
health-illness continuum. 
100-91Superior functioning in all areas (at home, at school and with peers), involved in a range or 
activities and has many interests (e.g., has hobbies or participates in extracurricular activities 
or belongs to an organized group such as Scouts, etc.). Likable, confident, ‚Äúeveryday‚Äù 
worries never get out of hand. Doing well in school, no symptoms
90-81 Good functioning in all areas. Secure in family, school and with peers. There may be 
transient difficulties and ‚Äúeveryday‚Äù worries that occasionally get out of hand (e.g. mild 
anxiety associated with an important exam, occasional ‚Äúblow ups‚Äù with siblings, parents or 
peers).
80-71 No more than slight impairment in functioning at home, at school, or with peers. Some 
disturbance of behavior or emotional distress may be present in response to life stresses (e.g., 
parental separations, deaths, births of a sib) but these are brief and interference with 
functioning is transient. Such children are only minimally disturbing to others who are not 
considered deviant by [CONTACT_420466].
70-61 Some difficulty in a single area, but generally functioning pretty well, (e.g., sporadic or 
isolated antisocial acts, such as occasionally playing hooky or petty theft; consistent minor 
difficulties with school work, mood changes of brief duration; fears and anxieties which do 
not lead to gross avoidance behavior; self doubts). Has some meaningful interpersonal 
relationships. Most people who do not know the child well would not consider him/her 
deviant but those who do know him/her well might express concern.
60-[ADDRESS_1085670] social areas or severe 
impairment of functioning in one area , such as might result from, for example, suicidal 
preoccupations and ruminations, school refusal and other forms of anxiety, obsessive rituals, 
major conversion symptoms, frequent anxiety attacks, frequent epi[INVESTIGATOR_788466].Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
104
Protocol 331-10-234
Confidential - Proprietary Information 104 Version 5.0, 05 Jul 202240-31 Major impairment in functioning in several areas and unable to function in one of these 
areas, i.e., disturbed at home, at school, with peers, or in the society at large, e.g., persistent 
aggression without clear instigation; markedly withdrawn and isolated behavior due to either 
mood or thought disturbance, suicidal attempts with clear lethal intent. Such children are 
likely to require special schooling or hospi[INVESTIGATOR_788467] (but this is 
not a sufficient criterion for inclusion in this category).
30-[ADDRESS_1085671] or in bed all day without 
taking part in social activities OR severe impairment in reality testing OR serious impairment 
in communication (e.g., sometimes incoherent or inappropriate).
20-11 Needs considerable supervision to prevent hurting other or self, e.g., frequently violent, 
repeated suicide attempts OR to maintain personal hygiene OR gross impairment in all forms 
of communication, e.g., severe abnormalities in verbal and gestural communication, marked 
social aloofness, stupor, etc.
10-1Needs constant supervision  (24-hour care) due to severely aggressive or self-destructive 
behavior or gross impairment in reality testing, communication, cognition, affect, or personal 
hygiene.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
105
Protocol 331-10-234
Confidential - Proprietary Information 105 Version 5.0, 05 Jul 2022Appendix 7 Clinical Global Impression - Severity of Illness Scale (CGI-S)
Considering your total clinical experience with this particular population, how mentally 
ill is the patient at this time?
0 = Not assessed 4 = Moderately ill
1 = Normal, not at all ill 5 = Markedly ill
2 = Borderline mentally ill 6 = Severely ill
3 = Mildly ill 7 = Among the most extremely ill patients
Guy, W. ed. ECDEU Assessment Manual for Psychopharmacology. US Dept of HEW, Publication No. 
(Adm):  76-338, 1976.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
106
Protocol 331-10-234
Confidential - Proprietary Information 106 Version 5.0, 05 Jul 2022Appendix 8 Clinical Global Impression - Improvement scale (CGI-I)
Rate total improvement whether or not in your judgment it is due entirely to drug 
treatment.  Compared to his/her condition at baseline, how much has patient changed?
0 = Not assessed 4 = No change
1 = Very much improved 5 = Minimally worse
2 = Much improved 6 = Much worse
3 = Minimally improved 7 = Very much worse
Guy, W. ed. ECDEU Assessment Manual for Psychopharmacology. US Dept of HEW, Publication No. 
(Adm): 76-338, 1976.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
107
Protocol 331-10-234
Confidential - Proprietary Information 107 Version 5.0, 05 Jul 2022Appendix 9 Pediatric Quality of Life Enjoyment and Satisfaction 
Questionnaire (P-Q-LES-Q)
INSTRUCTIONS:  This survey asks for your views about your general health, 
well-being, and feelings about your life.  Please answer EVERY question by [CONTACT_788521].  If you are not sure about how to answer a question, please 
give the best answer you can.  Remember, there are no right or wrong answers.
Very 
PoorPoor Fair Good Very 
Good
Over the past week, how have 
things been with...     
1. Your health? 1 2 3 4 5
2. Your mood or feelings? 1 2 3 4 5
3. School or learning? 1 2 3 4 5
4. Helpi[INVESTIGATOR_788468]? 1 2 3 4 5
5. Getting along with friends? 1 2 3 4 5
6. Getting along with your family? 1 2 3 4 5
7. Play or free time? 1 2 3 4 5
8. Getting things done? 1 2 3 4 5
9. Your love or affection? 1 2 3 4 5
10. Getting or buying things? [ADDRESS_1085672] where you live? 1 2 3 4 5
12. Paying attention? 1 2 3 4 5
13. Your energy level? 1 2 3 4 5
14. Feelings about yourself? 1 2 3 4 5
15. Overall, how has your life 
been?1 2 3 4 5Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
108
Protocol 331-10-234
Confidential - Proprietary Information 108 Version 5.0, 05 Jul 2022Appendix 10 Simpson Angus Scale (SAS)
Circle the appropriate score for each item:
1. GAIT
The patient is examined as he walks into the examining room; his gait, the swing of arms, his 
general posture; all form the basis for an overall score for this item.  This is rated as follows:
0 Normal
1 Mild diminution in swing while the patient is walking 
2 Obvious diminution in swing suggesting shoulder rigidity
3 Stiff gait with little or no arm swing noticeable
4 Rigid gait with arms slightly pronated; or stooped-shuffling gait with propulsion and 
retropulsion.
2. ARM DROPPI[INVESTIGATOR_582440], in a normal subject a stout slap is heard as the arms hit the sides.  In the patient with 
extreme Parkinson‚Äôs syndrome, the arms fall very slowly.
[ADDRESS_1085673] resistance; as though through glue
3. SHOULDER SHAKING
The subject‚Äôs arms are bent at a right angle at the elbow and taken one at a time by [CONTACT_657639]‚Äôs elbow.  The subject‚Äôs upper 
arm is pushed to and fro and the humerus is externally rotated.  The degree of resistance from 
normal to extreme rigidity is scored as follows:
[ADDRESS_1085674]‚Äôs biceps observed and simultaneously palpated.  The resistance to the procedure is rated.  
(The presence of cogwheel rigidity is noted separately.)
[ADDRESS_1085675] is held in one hand and then the fingers held by [CONTACT_4921]‚Äôs other hand with the 
wrist moved to extension, and both ulnar and radial deviation.  The resistance to this procedure is 
rated:
[ADDRESS_1085676] a frozen joint
6. HEAD ROTATION
The patient sits or stands and is told that you are going to move his head from side to side, that it 
will not hurt and that he should try and relax.  (Questions about pain in the cervical area or 
difficulty in moving his head should be obtained to avoid causing any pain.)  Clasp the patient‚Äôs 
head between the two hands with fingers on back of the neck.  Gently rotate the head in a circular 
motion [ADDRESS_1085677] is told to open his eyes and not to blink.  The glabella region is tapped at a steady, rapid 
speed.  The number of times patient blinks in succession is noted:
0 0-5 blinks
1 6-10 blinks
2 11-15 blinks
3 16-20 blinks
4 21 and more blinks
8. TREMOR
Patient is observed walking into examining room and then is examined for this item:
0 Normal
1 Mild finger tremor, obvious to sight and touch
2 Tremor of hand or arm occurring spasmodically
3 Persistent tremor of one or more limbs
4 Whole body tremor
9. SALIVATION
Patient is observed while talking and then asked to open his mouth and elevate his tongue.  The 
following ratings are given:
[ADDRESS_1085678] if the mouth is open and the tongue raised
2 Excess salivation is present and might occasionally result in difficulty in speaking
3 Speaking with difficulty because of excess salivation
4 Frank droolingClinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
110
Protocol 331-10-234
Confidential - Proprietary Information 110 Version 5.0, 05 Jul 202210. AKATHISIA
Patient is observed for restlessness.  If restlessness is noted, ask: ‚ÄúDo you feel restless or jittery 
inside; is it difficult to sit still?‚Äù  Subjective response is not necessary for scoring but patient 
report can help make the assessment.
0 No restlessness reported or observed
1 Mild restlessness observed
2 Moderate restlessness observed
3 Restlessness is frequently observed
4 Restlessness persistently observed
Adapted and used with permission by:  [CONTACT_788522], Angus JW. A rating scale for extrapyramidal side 
effects. Acta Psychiatrica Scandinavica. 1970;45(suppl 212):11-9.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
111
Protocol 331-10-234
Confidential - Proprietary Information 111 Version 5.0, 05 Jul 2022Appendix 11 Abnormal Involuntary Movement Scale (AIMS)
Movement ratings: rate highest severity observed. Rate 
movements that occur upon activation one less than those 
observed spontaneously.Code for items 1-7:
0 = None
1 = Minimal, may be extreme normal
2 = Mild
3 = Moderate
4 = Severe
(Circle One)
1. MUSCLES OF FACIAL EXPRESSION e.g. 
movements of forehead, eyebrows, periorbital 
area, cheeks; include frowning, blinking, smiling, 
grimacing0 1 2 3 4
2. LIPS AND PERIORAL AREA e.g. puckering, 
pouting, smacking.0 1 2 3 4
3. JAW e.g. biting, clenching, chewing, mouth 
opening, lateral movement.0 1 2 3 4FACIAL AND
ORAL
MOVEMENTS:
4. TONGUE Rate only increase in movement both 
in and out of mouth, not inability to sustain 
movement.0 1 2 3 4
5. UPPER (ARMS, WRISTS, HANDS, 
FINGERS) include choreic movements (i.e. 
rapid, objectively purposeless, irregular, 
spontaneous), athetoid movements (i.e. slow, 
irregular, complex, serpentine). Do not include 
tremor (i.e. repetitive, regular, rhythmic).0 1 2 3 4
EXTREMITY 
MOVEMENTS:
6. LOWER (LEGS, KNEES, ANKLES, TOES) 
e.g. lateral knee movement, foot tappi[INVESTIGATOR_007], heel 
droppi[INVESTIGATOR_007], foot squirming, inversion and eversion 
of foot0 1 2 3 4
TRUNK 
MOVEMENTS:7. NECK, SHOULDERS, HIPS e.g. rocking, 
twisting, squirming, pelvic gyrations0 1 2 3 4
None, normal 0
Minimal 1
Mild 2
Moderate 38. Severity of abnormal movements
Severe 4
None, normal 0
Minimal 1
Mild 2
Moderate 39. Incapacitation due to abnormal movements
Severe 4
No awareness 0
Aware, no distress 1
Aware, mild distress 2
Aware, moderate distress 3GLOBAL 
JUDGMENTS:
10. Patient‚Äôs awareness of abnormal movements
Rate only subject‚Äôs report.
Aware, severe distress 4
No 011. Any current problems with teeth or dentures?Yes 1
No 0DENTAL
STATUS:12. Does patient usually wear dentures?Yes 1
Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and 
Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
112
Protocol 331-10-234
Confidential - Proprietary Information 112 Version 5.0, 05 Jul 2022Appendix 12 Barnes Akathisia Rating Scale (BARS)
Instructions
Patient should be observed while they are seated, and then standing while engaged in 
neutral conversation (for a minimum of two minutes in each position).  Symptoms 
observed in other situations, for example while engaged in activity on the ward, may also 
be rated.  Subsequently, the subjective phenomena should be elicited by [CONTACT_657641].
Objective
0 Normal, occasional fidgety movements of the limbs
1 Presence of characteristic restless movements: shuffling or trampi[INVESTIGATOR_788469]/feet, or swinging one leg while sitting, or rocking from foot to foot or 
‚Äúwalking on the spot‚Äù when standing, but movements present for less than half the 
time observed
2 Observed phenomena, as described in (1) above, which are present for at least 
half the observation period
[ADDRESS_1085679] of the time. Unable to sit or lie down for more than a few minutes. Constant 
restlessness which is associated with intense distress and insomnia
Reproduced from:  Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-6.
¬© 1989 The Royal College of Psychiatrists.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
114
Protocol 331-10-234
Confidential - Proprietary Information 114 Version 5.0, 05 Jul 2022Appendix 13 Udvalg for Kliniske Undersogelser ([LOCATION_006]U)
The [LOCATION_006]U is used to assess side effects of subjects being treated with antipsychotic drugs 
and to determine whether there is a causal relationship.  Assessment of the individual 
symptoms is best accomplished by a semi structured interview with the subject during 
which the scale is gone through point by [CONTACT_788523].Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
115
Protocol 331-10-234
Confidential - Proprietary Information 115 Version 5.0, 05 Jul 2022THE [LOCATION_006]U SIDE EFFECTS RATING SCALE FOR THE
REGISTRATION OF UNWANTED EFFECTS OF PSYCHOTROPI[INVESTIGATOR_788470], October 1986
([LOCATION_006]U)Clinical Study Report 331-10-[ADDRESS_1085680] 3 days (see 
manual) Causal 
relationship Category 
of side 
effects Symptom 
9 0 1 2 3 Imp Pos Prb
1.1 Concentration Difficulties  
1.2 Asthenia/Lassitude/lncreased 
Fatiguability 
1.3 Sleepi[INVESTIGATOR_008]/Sedation 
1.4 Failing Memory 
1.5 Depression 
1.6 Tension/lnner Unrest 
1.[ADDRESS_1085681] 3 days (see 
manual) Causal 
relationship Category 
of side 
effects Symptom 
9 0 1 2 3 Imp Pos Prb
2.1 Dystonia
2.2 Rigidity
2.3 Hypokinesia/Akinesia
2.[ADDRESS_1085682] 3 days (see 
manual) Causal 
relationship Category 
of side 
effects Symptom 
9 0 1 2 3 Imp Pos Prb
3.1 Accommodation Disturbances
3.2 Increased Salivation
3.3 Reduced Salivation
3.4 Nausea/Vomiting
3.5 Diarrhoea
3.6 Constipation
3.7 Micturition Disturbances
3.8 Polyuria/Polydipsia
3.9 Orthostatic Dizziness
3.10 Palpi[INVESTIGATOR_814]/Tachycardia
3.[ADDRESS_1085683] 3 days (see 
manual) Causal 
relationship Category 
of side 
effects Symptom 
[ADDRESS_1085684] 3 days (see 
manual) Causal 
relationship Category 
of side 
effects Symptom 
9 0 1 2 3 Imp Pos Prb
4.14 Ejaculatory Dysfunction
4.15 Orgastic Dysfunction
4.16 Dry Vagina
4.17 Headache
4.17a -               Tension headache
4.17b -                Migraine
4.17c -                0ther forms
4.18 Physical Dependence
4.19 Psychic Dependence
Assessed by[CONTACT_788524]‚Äôs daily performance: Patient Doctor
0No side effects
 1Mild side effects that do not interfere with the patient‚Äôs performance
 2Side effects that interfere moderately with the patient‚Äôs performance
 3Side effects that interfere markedly with the patient‚Äôs performance
 
Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
121
Protocol 331-10-234
Confidential - Proprietary Information 121 Version 5.0, 05 Jul 2022Consequence 
0No action
 1More frequent assessment of the patient, but no reduction of dose, or occasional drug 
treatment of side effects
 2Reduction of dose or continuous drug, treatment of side effects
 3Discontinuation of drug or change to another preparation
  
Day Mth. Year Hour Min Date Time
Signature
 
[CONTACT_547502] 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
122
Protocol 331-10-234
Confidential - Proprietary Information 123 Version 5.0, 05 Jul 2022Clinician Form: Please complete each section below: 
1. Working memory: Trouble remembering things that people (parents, teachers, friends) 
have just said?
ÔÅØ Present 
during past 
week
ÔÅØ Not 
present in 
past weekÔÅØ Evident 
During Visit
ÔÅØ Not Evident 
During VisitÔÅØ Not drug related 
ÔÅØ Due to study 
drug 
ÔÅØ Other drug
ÔÅØ Drug/drug 
interaction
ÔÅØ Not applicableÔÅØ Mild
ÔÅØ Moderate
ÔÅØ Severe
ÔÅØ Extreme
ÔÅØ Not 
applicableÔÅØ Functional/ 
Role 
Impairment
ÔÅØ No 
Functional/ Role 
Impairment
ÔÅØ Not applicable
2. Attention/Vigilance: Trouble paying attention in class, home, or while playing games, 
watching TV, browsing the internet or using computers?
ÔÅØ Present 
during past 
week
ÔÅØ Not 
present in 
past weekÔÅØ Evident 
During Visit
ÔÅØ Not Evident 
During VisitÔÅØ Not drug related 
ÔÅØ Due to study 
drug 
ÔÅØ Other drug
ÔÅØ Drug/drug 
interaction
ÔÅØ Not applicableÔÅØ Mild
ÔÅØ Moderate
ÔÅØ Severe
ÔÅØ Extreme
ÔÅØ Not 
applicableÔÅØ Functional/ 
Role 
Impairment
ÔÅØ No 
Functional/ Role 
Impairment
ÔÅØ Not applicable
3. Verbal Learning/Memory: Difficulty remembering or learning words to things (book, 
songs, TV shows)? Trouble coming up with words in conversation?
ÔÅØ Present 
during past 
week
ÔÅØ Not 
present in 
past weekÔÅØ Evident 
During Visit
ÔÅØ Not Evident 
During VisitÔÅØ Not drug related 
ÔÅØ Due to study 
drug 
ÔÅØ Other drug
ÔÅØ Drug/drug 
interaction
ÔÅØ Not applicableÔÅØ Mild
ÔÅØ Moderate
ÔÅØ Severe
ÔÅØ Extreme
ÔÅØ Not 
applicableÔÅØ Functional/ 
Role 
Impairment
ÔÅØ No 
Functional/ Role 
Impairment
ÔÅØ Not applicable
4. Visual Learning/Memory: Patient has difficulty recalling how things look, such as shapes 
and colors?
ÔÅØ Present 
during past 
week
ÔÅØ Not 
present in 
past weekÔÅØ Evident 
During Visit
ÔÅØ Not Evident 
During VisitÔÅØ Not drug related 
ÔÅØ Due to study 
drug 
ÔÅØ Other drug
ÔÅØ Drug/drug 
interaction
ÔÅØ Not applicableÔÅØ Mild
ÔÅØ Moderate
ÔÅØ Severe
ÔÅØ Extreme
ÔÅØ Not 
applicableÔÅØ Functional/ 
Role 
Impairment
ÔÅØ No 
Functional/ Role 
Impairment
ÔÅØ Not applicable
5. Reasoning & Problem Solving: Trouble doing classwork or homework, solving math 
problems, doing puzzles?
ÔÅØ Present 
during past 
week
ÔÅØ Not 
present in 
past weekÔÅØ Evident 
During Visit
ÔÅØ Not Evident 
During VisitÔÅØ Not drug related 
ÔÅØ Due to study 
drug 
ÔÅØ Other drug
ÔÅØ Drug/drug 
interaction
ÔÅØ Not applicableÔÅØ Mild
ÔÅØ Moderate
ÔÅØ Severe
ÔÅØ Extreme
ÔÅØ Not 
applicableÔÅØ Functional/ 
Role 
Impairment
ÔÅØ No 
Functional/ Role 
Impairment
ÔÅØ Not applicableClinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
124
Protocol 331-10-234
Confidential - Proprietary Information 124 Version 5.0, 05 Jul [ZIP_CODE]. Speed of Processing: Feeling ‚Äúslowed down‚Äù, does it take you longer than usual to do 
things?
ÔÅØ Present 
during past 
week
ÔÅØ Not 
present in 
past weekÔÅØ Evident 
During Visit
ÔÅØ Not Evident 
During VisitÔÅØ Not drug related 
ÔÅØ Due to study 
drug 
ÔÅØ Other drug
ÔÅØ Drug/drug 
interaction
ÔÅØ Not applicableÔÅØ Mild
ÔÅØ Moderate
ÔÅØ Severe
ÔÅØ Extreme
ÔÅØ Not 
applicableÔÅØ Functional/ 
Role 
Impairment
ÔÅØ No 
Functional/ Role 
Impairment
ÔÅØ Not applicable
7. Social Cognition: Trouble understanding what other people intend, participating in social 
situations, or interacting with others?
ÔÅØ Present 
during past 
week
ÔÅØ Not 
present in 
past weekÔÅØ Evident 
During Visit
ÔÅØ Not Evident 
During VisitÔÅØ Not drug related 
ÔÅØ Due to study 
drug 
ÔÅØ Other drug
ÔÅØ Drug/drug 
interaction
ÔÅØ Not applicableÔÅØ Mild
ÔÅØ Moderate
ÔÅØ Severe
ÔÅØ Extreme
ÔÅØ Not 
applicableÔÅØ Functional/ 
Role 
Impairment
ÔÅØ No 
Functional/ Role 
Impairment
ÔÅØ Not applicableClinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
125
Protocol 331-10-234
Confidential - Proprietary Information 125 Version 5.0, 05 Jul 2022Appendix 15 Columbia-Suicide Severity Rating Scale (C-SSRS)
COLUMBIA-SUICIDE SEVERITY
RATING SCALE
(C-SSRS)
Baseline/Screening Version
Version 1/14/09
 Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; 
Fisher, P.; Zelazny, J.; Burke, A.; Oquendo, M.; Mann, J. 
Disclaimer:
This scale is intended to be used by [CONTACT_24659]. 
The questions contained in the Columbia-Suicide Severity Rating Scale are suggested probes. 
Ultimately, the determination of the presence of suicidal ideation or behavior depends on the 
judgment of the individual administering the scale.
Definitions of behavioral suicidal events in this scale are based on those used in The 
Columbia Suicide History Form, developed by [CONTACT_24660], MD and Maria Oquendo, 
MD, Conte Center for the Neuroscience of Mental Disorders (CCNMD), [LOCATION_001] State 
Psychiatric Institute, [ADDRESS_1085685], [LOCATION_001], NY, [ZIP_CODE]. (Oquendo M. A., Halberstam 
B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. 
In M.B. First [Ed.] Standardized Evaluation in Clinical Practice, pp. 103 -130, 2003.)
For reprints of the C-SSRS contact [CONTACT_24661], Ph.D., [LOCATION_001] State Psychiatric Institute, 
[ADDRESS_1085686], [LOCATION_001], [LOCATION_001], [ZIP_CODE]; inquiries and training requirements contact 
[EMAIL_848] 
ÔÉ£ 2008 The Research Foundation for Mental Hygiene, Inc.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
126
Protocol 331-10-234
Confidential - Proprietary Information 126 Version 5.0, 05 Jul 2022SUICIDAL IDEATION
Ask questions 1 and 2.  If both are negative, proceed to ‚ÄúSuicidal Behavior‚Äù section. 
If the answer to question 2 is ‚Äúyes‚Äù, ask questions 3, 4 and 5.  If the answer to 
question 1 or 2 is ‚Äúyes‚Äù, complete ‚ÄúIntensity of Ideation‚Äù section below.Lifetime: 
Time He/She 
Felt Most 
SuicidalPast [ADDRESS_1085687] you wished you were dead or wished you could go to sleep and not wake up? 
If yes, describe:Yes       No
‚ñ°    ‚ñ°Yes       No
‚ñ°    ‚ñ°
2.  Non-Specific Active Suicidal Thoughts
General, non-specific thoughts of wanting to end one‚Äôs life/commit suicide (e.g., ‚ÄúI‚Äôve thought 
about killing myself‚Äù) without thoughts of ways to kill oneself/associated methods, intent, or 
plan during the assessment period. 
Have you actually had any thoughts of killing yourself?
If yes, describe:Yes      No
‚ñ°    ‚ñ°Yes      No
‚ñ°    ‚ñ°
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent to 
Act
Subject endorses thoughts of suicide and has thought of at least one method during the 
assessment period. This is different than a specific plan with time, place or method details 
worked out (e.g.  thought of method to kill self but not a specific plan).  Includes person who 
would say, ‚ÄúI thought about taking an overdose but I never made a specific plan as to when, 
where or how I would actually do it‚Ä¶..and I would never go through with it.‚Äù 
Have you been thinking about how you might do this?
If yes, describe:Yes      No
‚ñ°    ‚ñ°Yes      No
‚ñ°    ‚ñ°
4.  Active Suicidal Ideation with Some Intent to Act, without Specific Plan
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such 
thoughts, as opposed to ‚ÄúI have the thoughts but I definitely will not do anything about them.‚Äù
Have you had these thoughts and had some intention of acting on them?
If yes, describe:Yes       No
‚ñ°    ‚ñ°Yes       No
‚ñ°    ‚ñ°
5.  Active Suicidal Ideation with Specific Plan and Intent
Thoughts of killing oneself with details of plan fully or partially worked out and subject has 
some intent to carry it out.
Have you started to work out or worked out the details of how to kill yourself? Do you intend 
to carry out this plan?
                                                                       
If yes, describe:Yes      No
‚ñ°    ‚ñ°Yes      No
‚ñ°    ‚ñ°Clinical Study Report 331-10-[ADDRESS_1085688] severe type of ideation 
(i.e.,1-[ADDRESS_1085689] severe ). Ask 
about time he/she was feeling the most suicidal. 
Lifetime -           Most Severe Ideation: ________ _______________________
Type # (1-5) Description of  Ideation
Past [ADDRESS_1085690] Severe Ideation:  ________ ________________________
Type # (1-5) Description of  IdeationLifetime: 
Time He/She 
Felt Most 
SuicidalPast [ADDRESS_1085691] you had these thoughts? 
(1) Less than once a week   (2) Once a week  (3)  2-5 times in week   (4) Daily or almost 
daily   (5) Many times each day____ ____
Duration
When you have the thoughts, how long do they last?
(1) Fleeting - few seconds or minutes            (4) 4-8 hours/most of day
(2) Less than 1 hour/some of the time            (5) More than 8 hours/persistent or continuous
(3) 1-4 hours/a lot of time____ ____
Controllability
Could/can you stop thinking about killing yourself or wanting to die if you want 
to?
(1) Easily able to control thoughts                   (4) Can control thoughts with a lot of difficulty 
(2) Can control thoughts with little difficulty  (5) Unable to control thoughts
(3) Can control thoughts with some difficulty (0) Does not attempt to control thoughts____ ____
Deterrents
Are there things - anyone or anything (e.g., family, religion, pain of death) - 
that stopped you from wanting to die or acting on thoughts of committing 
suicide?
(1) Deterrents definitely stopped you from       (4) Deterrents most likely did not stop you 
attempting suicide   
(2) Deterrents probably stopped you                 (5) Deterrents definitely did not stop you 
(3) Uncertain that deterrents stopped you         (0) Does not apply____ ____
Reasons for Ideation
What sort of reasons did you have for thinking about wanting to die or killing 
yourself?  Was it to end the pain or stop the way you were feeling (in other 
words you couldn‚Äôt go on living with this pain or how you were feeling) or was 
it to get attention, revenge or a reaction from others? Or both?
(1) Completely to get attention, revenge or (4) Mostly to end or stop the pain (you 
a reaction from others couldn‚Äôt go on living with the pain or
(2) Mostly to get attention, revenge or a how you were feeling).
reaction from others. (5) Completely to end or stop the pain (you
(3) Equally to get attention, revenge or a couldn‚Äôt go on living with the pain or  how
reaction from others and to end/stop you were feeling).
the pain. (0) Does not apply____ ____Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
128
Protocol 331-10-234
Confidential - Proprietary Information 128 Version 5.0, 05 Jul 2022SUICIDAL BEHAVIOR
(Check all that apply, so long as these are separate events; must ask about all types)Lifetime Past 1 
year
Actual Attempt: 
A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior 
was in part thought of as method to kill oneself. Intent does not have to be 100%.  If there is any 
intent/desire to die associated with the act, then it can be considered an actual suicide attempt. There 
does not have to be any injury or harm, just the potential for injury or harm. If person pulls 
trigger while gun is in mouth but gun is broken so no injury results, this is considered an attempt.  
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the 
behavior or circumstances. For example, a highly lethal act that is clearly not an accident so no other 
intent but suicide can be inferred (e.g., gunshot to head, jumpi[INVESTIGATOR_24608] a high floor/story). 
Also, if someone denies intent to die, but they thought that what they did could be lethal, intent may be 
inferred. 
Have you made a suicide attempt?
Have you done anything to harm yourself?
Have you done anything dangerous where you could have died?
What did you do?
Did you______ as a way to end your life? 
Did you want to die (even a little) when you_____? 
Were you trying to end your life when you _____?
Or did you think it was possible you could have died from_____?
Or did you do it purely for other reasons / without ANY intention of killing yourself 
(like to relieve stress, feel better, get sympathy, or get something else to happen)?  
(Self-Injurious Behavior without suicidal intent)
If yes, describe:
Has subject engaged in Non-Suicidal Self-Injurious Behavior?Yes      No
‚ñ°   ‚ñ°
Total # of
Attempts
Yes    No
‚ñ°   ‚ñ°Yes      No
‚ñ°   ‚ñ°
Total # of
Attempts
Yes    No
‚ñ°   ‚ñ°
Interrupted Attempt:  
When the person is interrupted (by [CONTACT_24662]) from starting the potentially self-injurious 
act (if not for that, actual attempt would have occurred).
Overdose: Person has pi[INVESTIGATOR_24609].  Once they ingest any pi[INVESTIGATOR_3353], this 
becomes an attempt rather than an interrupted attempt. Shooting: Person has gun pointed toward self, 
gun is taken away by [CONTACT_24663], or is somehow prevented from pulling trigger. Once they pull the 
trigger, even if the gun fails to fire, it is an attempt. Jumpi[INVESTIGATOR_007]: Person is poised to jump, is grabbed and 
taken down from ledge. Hanging: Person has noose around neck but has not yet started to hang - is 
stopped from doing so.
Has there been a time when you started to do something to end your life but 
someone or something stopped you before you actually did anything?
If yes, describe:Yes      No
‚ñ°   ‚ñ°
Total # of 
interruptedYes      No
‚ñ°   ‚ñ°
Total # of 
interrupted
Aborted Attempt:  
When person begins to take steps toward making a suicide attempt, but stops themselves before they 
actually have engaged in any self-destructive behavior. Examples are similar to interrupted attempts, 
except that the individual stops him/herself, instead of being stopped by [CONTACT_6615].
Has there been a time when you started to do something to try to end your life but 
you stopped yourself before you actually did anything?
If yes, describe:Yes      No
‚ñ°   ‚ñ°
Total # of
aborted
______Yes      No
‚ñ°   ‚ñ°
Total # of
aborted
______
Preparatory Acts or Behavior:
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a 
verbalization or thought, such as assembling a specific method (e.g., buying pi[INVESTIGATOR_3353], purchasing a gun) or 
preparing for one‚Äôs death by [CONTACT_20673] (e.g., giving things away, writing a suicide note). 
Have you taken any steps towards making a suicide attempt or preparing to kill 
yourself (such as collecting pi[INVESTIGATOR_3353], getting a gun, giving valuables away or writing a 
suicide note )?
If yes, describe:Yes      No
‚ñ°   ‚ñ°Yes      No
‚ñ°   ‚ñ°
Suicidal Behavior:
Suicidal behavior was present during the assessment period?Yes      No
‚ñ°   ‚ñ°Yes      No
‚ñ°   ‚ñ°Clinical Study Report 331-10-[ADDRESS_1085692] Recent 
Attempt Date:Most Lethal 
Attempt Date:Initial/
First Attempt 
Date:
Actual Lethality/Medical Damage:  
0.  No physical damage or very minor physical damage (e.g., surface scratches).
1.  Minor physical damage (e.g., lethargic speech; first-degree burns; mild 
bleeding; sprains).
2.  Moderate physical damage; medical attention needed (e.g., conscious but 
sleepy, somewhat responsive; second-degree burns; bleeding of major 
vessel).
3.  Moderately severe physical damage; medical  hospi[INVESTIGATOR_788471] (e.g., comatose with reflexes intact; third-degree 
burns less than 20% of body; extensive blood loss but can recover; major 
fractures).
4.  Severe physical damage; medical hospi[INVESTIGATOR_24611] 
(e.g., comatose without reflexes; third-degree burns over 20% of body; 
extensive blood loss with unstable vital signs; major damage to a vital area).
5.  DeathEnter Code
_________Enter Code
_________Enter Code
_________
Potential Lethality: Only Answer if Actual Lethality=0
Likely lethality of actual attempt if no medical damage (the following examples, 
while having no actual medical damage, had potential for very serious lethality: 
put gun in mouth and pulled the trigger but gun fails to fire so no medical 
damage; laying on train tracks with oncoming train but pulled away before run 
over).
0 = Behavior not likely to result in injury
1 = Behavior likely to result in injury but not likely to cause death
2 = Behavior likely to result in death despi[INVESTIGATOR_156187]
_________Enter Code
_________Enter Code
_________Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
130
Protocol 331-10-234
Confidential - Proprietary Information 130 Version 5.0, 05 Jul 2022COLUMBIA-SUICIDE SEVERITY
RATING SCALE
(C-SSRS)
Since Last Visit
Version 1/14/09
Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; 
Fisher, P.; Zelazny, J.; Burke, A.; Oquendo, M.; Mann, J. 
Disclaimer:
This scale is intended to be used by [CONTACT_24659]. 
The questions contained in the Columbia-Suicide Severity Rating Scale are suggested probes. 
Ultimately, the determination of the presence of suicidal ideation or behavior depends on the 
judgment of the individual administering the scale.
Definitions of behavioral suicidal events in this scale are based on those used in The 
Columbia Suicide History Form, developed by [CONTACT_24660], MD and Maria Oquendo, 
MD, Conte Center for the Neuroscience of Mental Disorders (CCNMD), [LOCATION_001] State 
Psychiatric Institute, [ADDRESS_1085693], [LOCATION_001], NY, [ZIP_CODE]. (Oquendo M. A., Halberstam 
B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. 
In M.B. First [Ed.] Standardized Evaluation in Clinical Practice, pp. 103 -130, 2003.)
 For reprints of the C-SSRS contact [CONTACT_24661], Ph.D., [LOCATION_001] State Psychiatric Institute, 
[ADDRESS_1085694], [LOCATION_001], [LOCATION_001], [ZIP_CODE]; inquiries and training requirements contact 
[EMAIL_848] 
ÔÉ£ 2008 The Research Foundation for Mental Hygiene, Inc.Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
131
Protocol 331-10-234
Confidential - Proprietary Information 131 Version 5.0, 05 Jul 2022SUICIDAL IDEATION
Ask questions 1 and 2.  If both are negative, proceed to ‚ÄúSuicidal Behavior‚Äù section. If the 
answer to question 2 is ‚Äúyes‚Äù, ask questions 3, 4 and 5.  If the answer to question 1 or 2 is 
‚Äúyes‚Äù, complete ‚ÄúIntensity of Ideation‚Äù section below.Since Last 
Visit
1.  Wish to be Dead 
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up. 
Have you wished you were dead or wished you could go to sleep and not wake up? 
If yes, describe:Yes       No
 ‚ñ°    ‚ñ°
2.  Non-Specific Active Suicidal Thoughts
General, non-specific thoughts of wanting to end one‚Äôs life/commit suicide (e.g., ‚ÄúI‚Äôve thought about killing 
myself‚Äù) without thoughts of ways to kill oneself/associated methods, intent, or plan during the assessment period. 
Have you actually had any thoughts of killing yourself?
If yes, describe: Yes      No
  ‚ñ°    ‚ñ°
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period. This is 
different than a specific plan with time, place or method details worked out (e.g.,  thought of method to kill self 
but not a specific plan).  Includes person who would say, ‚ÄúI thought about taking an overdose but I never made a 
specific plan as to when, where or how I would actually do it‚Ä¶..and I would never go through with it.‚Äù 
Have you been thinking about how you might do this?
If yes, describe: Yes      No
  ‚ñ°    ‚ñ°
4.  Active Suicidal Ideation with Some Intent to Act, without Specific Plan
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts, as 
opposed to ‚ÄúI have the thoughts but I definitely will not do anything about them.‚Äù
Have you had these thoughts and had some intention of acting on them? 
If yes, describe:Yes       No
  ‚ñ°    ‚ñ°
5.  Active Suicidal Ideation with Specific Plan and Intent
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it 
out.
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this 
plan?
                                                                       
If yes, describe: Yes      No
  ‚ñ°    ‚ñ°Clinical Study Report 331-10-[ADDRESS_1085695] severe type of ideation (i.e.,1-[ADDRESS_1085696] severe ).
                                            
Most Severe Ideation:             _____              _________________________________________                                              
                                                                                                           Type # (1-5)                                Description of  IdeationMost 
Severe
Frequency
How many times have you had these thoughts? 
(1) Less than once a week    (2) Once a week   (3)  2-5 times in week    (4) Daily or almost daily    
(5) Many times each day____
Duration
When you have the thoughts, how long do they last?
(1) Fleeting - few seconds or minutes                                    (4) 4-8 hours/most of day
(2) Less than 1 hour/some of the time                                    (5) More than 8 hours/persistent or continuous
(3) 1-4 hours/a lot of time____
Controllability
Could/can you stop thinking about killing yourself or wanting to die if you want to?
(1) Easily able to control thoughts                                          (4) Can control thoughts with a lot of difficulty
(2) Can control thoughts with little difficulty                         (5) Unable to control thoughts
(3) Can control thoughts with some difficulty                        (0) Does not attempt to control thoughts____
Deterrents
Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you 
from wanting to die or acting on thoughts of committing suicide?
(1) Deterrents definitely stopped you from attempting suicide      (4) Deterrents most likely did not stop you 
(2) Deterrents probably stopped you                                               (5) Deterrents definitely did not stop you 
(3) Uncertain that deterrents stopped you                                       (0) Does not apply____
Reasons for Ideation
What sort of reasons did you have for thinking about wanting to die or killing yourself?  Was 
it to end the pain or stop the way you were feeling (in other words you couldn‚Äôt go on living 
with this pain or how you were feeling) or was it to get attention, revenge or a reaction from 
others? Or both?
(1) Completely to get attention, revenge or a reaction from others. (4) Mostly to end or stop the pain (you 
(2) Mostly to get attention, revenge or a reaction from others. couldn‚Äôt go on living with the pain or 
(3) Equally to get attention, revenge or a reaction from others how you were feeling).
     and to end/stop the pain. (5) Completely to end or stop the pain
(you couldn‚Äôt go on living with the
pain or how you were feeling).
(0) Does not apply
                                                                      ____Clinical Study Report 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
133
Protocol 331-10-234
Confidential - Proprietary Information 133 Version 5.0, 05 Jul 2022SUICIDAL BEHAVIOR
(Check all that apply, so long as these are separate events; must ask about all types)Since Last 
Visit
Actual Attempt: 
A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part 
thought of as method to kill oneself. Intent does not have to be 100%.  If there is any intent/desire to die associated 
with the act, then it can be considered an actual suicide attempt. There does not have to be any injury or 
harm, just the potential for injury or harm. If person pulls trigger while gun is in mouth but gun is broken so no 
injury results, this is considered an attempt.  
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or 
circumstances. For example, a highly lethal act that is clearly not an accident so no other intent but suicide can be 
inferred (e.g., gunshot to head, jumpi[INVESTIGATOR_24608] a high floor/story). Also, if someone denies intent to die, 
but they thought that what they did could be lethal, intent may be inferred. 
Have you made a suicide attempt?
Have you done anything to harm yourself?
Have you done anything dangerous where you could have died?
What did you do?
Did you______ as a way to end your life? 
Did you want to die (even a little) when you_____? 
Were you trying to end your life when you _____?
Or did you think it was possible you could have died from_____?
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to 
relieve stress, feel better, get sympathy, or get something else to happen)?  (Self-Injurious Behavior 
without suicidal intent)
If yes, describe:
Has subject engaged in Non-Suicidal Self-Injurious Behavior?Yes      No
‚ñ°   ‚ñ°
Total # of
Attempts
______
Yes     No
‚ñ°   ‚ñ°
Interrupted Attempt:  
When the person is interrupted (by [CONTACT_24662]) from starting the potentially self-injurious act (if not 
for that, actual attempt would have occurred).
Overdose: Person has pi[INVESTIGATOR_24609].  Once they ingest any pi[INVESTIGATOR_3353], this becomes an 
attempt rather than an interrupted attempt. Shooting: Person has gun pointed toward self, gun is taken away by 
[CONTACT_24663], or is somehow prevented from pulling trigger. Once they pull the trigger, even if the gun fails to fire, 
it is an attempt. Jumpi[INVESTIGATOR_007]: Person is poised to jump, is grabbed and taken down from ledge. Hanging: Person has 
noose around neck but has not yet started to hang - is stopped from doing so.
Has there been a time when you started to do something to end your life but someone or 
something stopped you before you actually did anything?
If yes, describe:Yes      No
‚ñ°   ‚ñ°
Total # of 
interrupted
______
Aborted Attempt:  
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have 
engaged in any self-destructive behavior. Examples are similar to interrupted attempts, except that the individual 
stops him/herself, instead of being stopped by [CONTACT_6615].
Has there been a time when you started to do something to try to end your life but you 
stopped yourself before you actually did anything?
If yes, describe:Yes      No
‚ñ°   ‚ñ°
Total # of
aborted
_____
Preparatory Acts or Behavior:
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a 
verbalization or thought, such as assembling a specific method (e.g., buying pi[INVESTIGATOR_3353], purchasing a gun) or preparing 
for one‚Äôs death by [CONTACT_20673] (e.g., giving things away, writing a suicide note). 
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such 
as collecting pi[INVESTIGATOR_3353], getting a gun, giving valuables away or writing a suicide note)?
If yes, describe:Yes      No
‚ñ°   ‚ñ°
Suicidal Behavior:
Suicidal behavior was present during the assessment period?Yes      No
‚ñ°   ‚ñ°
Completed Suicide:    Yes    No
‚ñ°   ‚ñ°Clinical Study Report 331-10-[ADDRESS_1085697] Lethal 
Attempt 
Date:
Actual Lethality/Medical Damage:  
0.  No physical damage or very minor physical damage (e.g., surface scratches).
1.  Minor physical damage (e.g., lethargic speech; first-degree burns; mild bleeding; sprains).
2.  Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second-
degree burns; bleeding of major vessel).
3.  Moderately severe physical damage; medical  hospi[INVESTIGATOR_24610] (e.g., comatose 
with reflexes intact; third-degree burns less than 20% of body; extensive blood loss but can recover; major 
fractures).
4.  Severe physical damage; medical hospi[INVESTIGATOR_24611] (e.g., comatose without reflexes; 
third-degree burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital 
area).
5.  DeathEnter Code
________
Potential Lethality: Only Answer if Actual Lethality=0
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical 
damage, had potential for very serious lethality: put gun in mouth and pulled the trigger but gun fails to fire so no 
medical damage; laying on train tracks with oncoming train but pulled away before run over).
0 = Behavior not likely to result in injury
1 = Behavior likely to result in injury but not likely to cause death
2 = Behavior likely to result in death despi[INVESTIGATOR_156187]
________Clinical Study Report 331-10-[ADDRESS_1085698] and papi[INVESTIGATOR_788472]; areolar diameter 
increased
[ADDRESS_1085699] and areola enlarged, no 
contour separation
4 Coarse, curly, abundant but 
amount less than adultAreola and papi[INVESTIGATOR_788473]
5 Adult feminine triangle, spread 
to medial surface of thighsMature; nipple projects, areola 
part of the general breast contour
Classification of Sex Maturity Stages in Boys
Stage Pubic Hair Penis Testes
1 None Preadolescent Preadolescent
2 Scanty, long, slightly 
pi[INVESTIGATOR_788474], pi[INVESTIGATOR_788475]
3 Darker, starts to curl, 
small amountLonger Larger
4 Resembles adult type 
but less in quantity; 
coarse, curlyLarger; glans and 
breadth increase in sizeLarger, scrotum dark
[ADDRESS_1085700] read and understand the protocol (including the 
Investigator's Brochure) and agree that it contains all the ethical, legal and scientific information 
necessary to conduct this trial in accordance with the principles of Good Clinical Practices and as 
described herein and in the sponsor's (or designee's) Clinical Trial Agreement.
I will provide copi[INVESTIGATOR_35008], nurses, and other professional personnel to 
whom I delegate trial responsibilities. I will discuss the protocol with them to ensure that they are 
sufficiently informed regarding the investigational new drug, OPC-[ZIP_CODE], the concurrent 
medications, the efficacy and safety parameters and the conduct of the trial in general. I am 
aware that this protocol must be approved by [CONTACT_4707] (IRB) or receive a 
favorable opi[INVESTIGATOR_572581] (IEC) responsible for such matters in the 
clinical trial facility where OPC-[ZIP_CODE] will be tested prior to commencement of this trial. I agree to 
adhere strictly to the attached protocol (unless amended in the manner set forth in the sponsor's 
Clinical Trial Agreement, at which time I agree to adhere strictly to the protocol as amended).
I understand that this IRB- or IEC-approved protocol will be submitted to the appropriate 
regulatory authority/ies by [CONTACT_456]. I agree that clinical data entered on case report forms by 
[CONTACT_444493], such as for submission to 
governmental regulatory authorities or in combination with clinical data gathered from other 
research sites, whenever applicable. I agree to allow sponsor and designee monitors and 
auditors full access to all medical records at the research facility for subjects screened or enrolled 
in the trial.
I agree to await IRB/IEC approval before implementation of any substantial amendments to this 
protocol. If, however, there is an immediate hazard to subjects, I will implement the amendment 
immediately, and provide the information to the IRB/IEC within the required local applicable 
timelines. Administrative changes to the protocol will be transmitted to the IRB/IEC for 
informational purposes only, if required by [CONTACT_427].
I agree to provide all subjects with informed consent forms, as required by [CONTACT_35212]. I agree to report to the sponsor any adverse experiences in 
accordance with the terms of the sponsor's Clinical Trial Agreement and the relevant regional 
regulation(s) and guideline(s). I further agree to provide all required information regarding 
financial certification or disclosure to the sponsor for all investigators and sub-investigators in 
accordance with the terms of the relevant regional regulation(s). I understand that participation in 
the protocol involves a commitment to publish the data from this trial in a cooperative publication 
before publication of efficacy and safety results on an individual basis may occur, and I consent to 
be acknowledged in any such cooperative publications that result.
____________________________ _____________________________ ___________
Principal Investigator [INVESTIGATOR_788476] 331-10-234 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
196
7KLVSDJHLVDPDQLIHVWDWLRQRIDQHOHFWURQLFDOO\FDSWXUHGVLJQ DWXUH
6,*1$785(3$*(
'RFXPHQW1DPHB&RXQWU\6SHFLILF3URWRFRO$PHQGPHQW B+XQJDU\
'RFXPHQW1XPEHU
6LJQHGE\ 0HDQLQJRI6LJQDWXUH 6HUYHU'DWH
GG000
\\\\KKPLQ
87&WLPH]RQH
&OLQLFDO$SSURYDO -XQ

%LRVWDWLVWLFV$SSURYDO -XQ
&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOLFGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
[COMPANY_003]
[COMPANY_003]